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Abstract
In vitro studies of cardiovascular biology have often relied on static assays using plasma or isolated
blood cells in the past. Microfluidic technologies offer a unique opportunity to study the mechanisms of
hemostasis and thrombosis under physiologically relevant conditions. This thesis describes a
microfluidic approach to model cardiovascular diseases and evaluate therapeutic candidates. In our
studies, we recreated sterile occlusive thrombosis under a wide range of pressure drops and investigated
the effect of hemodynamic forces on neutrophil activities during clot formation. We discovered that high
interstitial hemodynamic forces (> 70 mmHg/mm-clot) can drive physically entrapped neutrophils to
rapidly form neutrophil extracellular trap (NET) during sterile occlusive thrombosis, offering an
explanation for the rapid neutrophil DNA release in mouse ferric chloride carotid artery injury models and
the extracellular nucleosomes detected in thrombi/plasma obtained from patients with stroke, myocardial
infarction, and disseminated intravascular coagulation.
In addition to modeling occlusive thrombus formation, we also characterized clotting profiles of patient
populations and recreated disease phenotypes. Through modifying our microfluidic clotting assay, we
reduced the risk of contact activation during sample preparation and increased the dynamic range for
drug testing. Hemophilia assays phenocopying the bleeding disorder was developed using healthy adult
blood treated with a low-activity factor variant or neutralizing antibodies. The assays could enable rapid
screening of novel hemophilic agents in a high-throughput fashion.
We also used our microfluidic clotting assays to measure clotting rates of neonatal patients with
congenital heart disease, and we found reduced platelet deposition and fibrin generation ex vivo for
neonates compared to healthy adults. Neonatal patients also displayed heightened sensitivity to
antithrombotic drugs. The majority of the patients who underwent surgical operations had increased
platelet deposition 24 hours after surgery whereas the trend for fibrin polymerization was less clear. The
significant increase in platelet response demonstrated the need for postoperative pharmacological
protections. Our results in a phase I clinical trial showed that cangrelor is an excellent candidate for
preventing shunt thrombosis in neonatal patients after surgical operations.
Using microfluidic devices, we demonstrated that thrombosis-and-hemostasis-on-a-chip could help us
understand the mechanisms of cardiovascular biology and evaluate therapeutic candidates.
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ABSTRACT
A MICROFLUIDIC APPROACH FOR INVESTIGATING THROMBOSIS AND
HEMOSTASIS: FROM DISEASE MODELS TO DRUG TESTING
Xinren Yu
Scott L. Diamond

In vitro studies of cardiovascular biology have often relied on static assays using
plasma or isolated blood cells in the past. Microfluidic technologies offer a unique
opportunity to study the mechanisms of hemostasis and thrombosis under physiologically
relevant conditions. This thesis describes a microfluidic approach to model cardiovascular
diseases and evaluate therapeutic candidates. In our studies, we recreated sterile occlusive
thrombosis under a wide range of pressure drops and investigated the effect of
hemodynamic forces on neutrophil activities during clot formation. We discovered that
high interstitial hemodynamic forces (> 70 mmHg/mm-clot) can drive physically entrapped
neutrophils to rapidly form neutrophil extracellular trap (NET) during sterile occlusive
thrombosis, offering an explanation for the rapid neutrophil DNA release in mouse ferric
chloride carotid artery injury models and the extracellular nucleosomes detected in
thrombi/plasma obtained from patients with stroke, myocardial infarction, and
disseminated intravascular coagulation.
In addition to modeling occlusive thrombus formation, we also characterized
clotting profiles of patient populations and recreated disease phenotypes. Through
modifying our microfluidic clotting assay, we reduced the risk of contact activation during
sample preparation and increased the dynamic range for drug testing. Hemophilia assays
phenocopying the bleeding disorder was developed using healthy adult blood treated with
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a low-activity factor variant or neutralizing antibodies. The assays could enable rapid
screening of novel hemophilic agents in a high-throughput fashion.
We also used our microfluidic clotting assays to measure clotting rates of neonatal
patients with congenital heart disease, and we found reduced platelet deposition and fibrin
generation ex vivo for neonates compared to healthy adults. Neonatal patients also
displayed heightened sensitivity to antithrombotic drugs. The majority of the patients who
underwent surgical operations had increased platelet deposition 24 hours after surgery
whereas the trend for fibrin polymerization was less clear. The significant increase in
platelet response demonstrated the need for postoperative pharmacological protections.
Our results in a phase I clinical trial showed that cangrelor is an excellent candidate for
preventing shunt thrombosis in neonatal patients after surgical operations.
Using microfluidic devices, we demonstrated that thrombosis-and-hemostasis-ona-chip could help us understand the mechanisms of cardiovascular biology and evaluate
therapeutic candidates.
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Chapter 1: Introduction
1.1 Thrombosis and Hemostasis
Hemostatic system exists to limit blood loss upon vascular injury. While the formation of a
hemostatic plug is beneficial when there is a breach in a blood vessel, excessive clotting inside the
vessel lumen can compromise circulation and the oxygen supply in the surrounding tissue.
Thrombosis can result in heart diseases and stroke, which are two of the top 5 leading causes of
death in 2017 according to National center health statistics. The major players in clotting process
include blood cells, coagulation factors, endothelium, and hemodynamics.
1.2 Blood cells
Erythrocytes, platelets, and leukocytes have all been found to participate in clot formation.
Erythrocytes or red blood cells (RBCs) are the most abundant blood cells (4-6 million cells/µl) in
our body, and they can influence blood clotting in a number of ways. RBCs can adhere to activated
platelets, activated neutrophils, and polymerized fibrin in plasma [1] at depressed venous shear
rates. The volume percentage of red blood cells in blood, known as hematocrit (35-50% on
average), directly affects platelet margination towards vessel walls and blood viscosity. Elevated
hematocrit has been found to increase the risk of arterial thrombosis. Individuals with high
hematocrit had 30% more incidence of ischemic heart diseases in British Regional Heart Study [2].
Abnormal erythrocytes can cause increased risk of thrombotic events as well. In contrast to the
flexible and round RBCs, sickle cell disease patients have erythrocytes that are rigid, sticky, and
shaped like crescent moons. These patients can experience vaso-occlusive crisis during which the
sickled RBCs obstruct the circulation in blood vessels causing painful ischemic injuries.
Platelets are the second abundant blood cells (150,000-450,000 cells/µl) in our body and are the
corner stone in clot formation. A variety of platelet agonists can engage different platelet surface
receptors. The different signaling pathways then converge at intracellular calcium mobilization,
which eventually lead to integrin activation, granule release, and shape change in platelets. When
endothelium is disrupted, subendothelial matrix proteins are exposed to the blood flow. Platelets
can adhere to collagen (types I, III, and VI) through glycoprotein VI (GPVI) receptors and activate
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integrins (2β1 and IIbβ3). The former is necessary for firm adhesion between platelets and
collagen and the latter is required for fibrinogen-mediated tight adhesion among platelets. Platelets
can also form transient bond with von Willebrand Factor (vWF) through glycoprotein Ib (GPIb)
receptors. The initial layer of platelets can then release granule proteins such as adenosine
diphosphate (ADP) and thromboxane A2 (TXA2) to further activate and capture incoming platelets
in the boundary layer.
Leukocytes or white blood cells (WBCs) are traditionally considered to be the major player in
infection and inflammation. Leukocytes can be categorized into five major types: neutrophils,
eosinophils, basophils, lymphocytes, and monocytes. Neutrophils make up 62% of the circulating
WBCs in our body and are the first responders to bacteria and fungi infection. Neutrophils can
directly interact with platelets coagulation cascade through proteases such as cathepsin G and
elastase and the release of neutrophil extracellular traps (NETs). Monocytes, which make up about
5% of the WBCs, can express tissue factor (TF). TF can initiate the extrinsic pathway of
coagulation. Monocyte can also differentiate into macrophages that can either promote or stabilize
plaque formation in atherosclerosis.
1.3 Coagulation Cascade
The upstream reactions in the coagulation pathway are commonly divided into two branches:
intrinsic and extrinsic. In the intrinsic or contact pathway, negatively charged surface activates
Factor XII (FXII), which then leads to FXI activation. Activated FXI (FXIa) converts FIX to FIXa.
FVIIIa associates with FIXa to activate FX. In the extrinsic pathway, tissue factor binds to activated
FVII to accelerate FXa production. The intrinsic and extrinsic pathways converge at FXa
generation. FXa forms complex with FVa to convert prothrombin to thrombin, a critical step in the
coagulation cascade. Thrombin can potently induce platelet activation through interactions with
protease-activated receptors (PAR1 and PAR4). Thrombin is also responsible for the conversion
of fibrinogen to fibrin, another major structural component of thrombus formation. In addition, FXIII
activated by thrombin can crosslink fibrin clots to further stabilize clots.
1.4 Vasculature
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Endothelium make up the inner lining of the blood vessels. Normally intact endothelium protect
platelets from activation through the production of nitric oxide and prostaglandin I2. Similar to
platelets, endothelial cells also express PAR1 and can be activated by thrombin. Upon activation,
endothelial cells can release Weibel-Palade body content including vWF and tissue plasminogen
activator (tPA). Tissue type plasminogen activator enables plasmin generation and fibrin
degradation. In pathological conditions such as hypoxia, inflamed endothelium can promote
neutrophil adhesion to the vessel wall, which then recruit platelets to form venous thrombi.
1.5 Hemodynamics
While many traditional clotting assays are performed under static conditions, thrombus formation
in vivo is governed by the hemodynamics as well. Blood is a non-Newtonian fluid as its apparent
viscosity varies depending on the shear rate, hematocrit level, and vessel diameter. At depressed
shear rates such as in the veins, the viscosity can reach 10 centipoise (cP) whereas the value is
closer to 3-4 cP in arteries. And the dependency on shear rate has been shown to be greater when
the hematocrit is higher. Because less RBCs are present in microcirculation, the reduced local
hematocrit results in lower local viscosity.
Shear rate experienced by the vessel walls has been estimated in vivo, in vitro, and in silica. It can
range from less than 100s -1 in vena cava all the way to >1500 s-1 in arterioles [3]. During clot
formation, the vessel luminal space continues to decrease, and the hydrodynamic resistance
continues to rise. In pathological conditions like stenosis, shear rates can reach as high as 5000s1. While

the shear stress exerted on growing clot can influence clot deformation and disaggregation,

the flow velocity can affect the residence time of soluble proteins such as coagulation factors and
clot releasate. Before vessel occlusion, majority of the blood flow occurs outside the growing clot
due to the permeability disparity between the inside and outside regions of the thrombus. Upon
vessel occlusion, the concept of bulk flow shear rate/shear stress no longer holds. Instead, the
transthrombus pressure drop drives Darcy flow permeation through the porous clot.
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Chapter 2: Hemodynamic force trigger rapid NETosis in sterile thrombotic
occlusions
2.1 Introduction
Activated neutrophils can release their DNA when triggered by endotoxin or cytokines [4],
pathogenic microorganisms [5], platelet-derived high-mobility group protein box 1 (HMGB1) [6,7],
and autoantibodies [8]. Neutrophil extracellular traps (NETs) have antimicrobial activity [4] and
provide components for contact activation of the coagulation pathway [9–11] and for tissue factor
pathway inhibitor (TFPI) degradation [12]. However, NETs can also contribute to tissue damage
[13]. NETs have been implicated in the pathogenesis of sepsis [14], venous thrombosis [7,15],
arterial thrombosis [6,16], disseminated intravascular coagulation (DIC) [17], trauma [18,19],
transfusion related acute lung injury (TRALI) [20], and autoimmune vasculitis [8].
During thrombotic or hemostatic events, sterile blood clotting is typically dominated initially by
platelet accumulation with neutrophils becoming localized at later stages [21]. Display of endothelial
or platelet P-selectin facilitates PSGL-1-dependent neutrophil adhesion at venous flow conditions
[22]. Platelet activation by thrombin, ADP, and collagen can also induce NETs, through HMGB1
release [6]. The platelet-derived disulfide-HMBG1 drives NETosis by activating neutrophil receptor
for advanced glycation end products (RAGE), a pathway present in the partial stenosis model of
deep vein thrombosis (DVT) in mouse [7]. HMGB1 and NETs have also been detected in thrombi
following acute myocardial infarction [16]. High dose lipopolysaccharide (LPS, 5 µg/mL) or septic
plasma can activate platelet toll-like receptor 4 (TLR4) which can then drive NETosis with
bacteriostatic activity [14].
Critical events during NETosis include disruption of the nuclear membrane and chromatin
decondensation, followed by rupture of the plasma membrane [23]. Often, NETosis utilizes reactive
oxygen species (ROS) and/or peptidylarginine deiminase 4 (PAD4) for chromatin decondensation
via formation of citrullinated histones [24–26]. The extracellular decoration of neutrophil released
DNA with elastase, myeloperoxidase, and citrullinated histone are key diagnostic features of
NETosis [23]. NET formation has been studied in the presence of flow using endotoxin stimulation
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or phorbol ester stimulation [27,28]. However, the distinct role of pathophysiological hemodynamic
force as a trigger or cofactor for NETosis has not been resolved.
We hypothesized that hemodynamic shearing forces may play a role in NET formation during
thrombosis. Using microfluidics, clot formation can be modeled by flowing whole blood over
collagen surfaces under conditions that either prevent or promote thrombin formation and fibrin
deposition. As a clot grows under flow, fluid shear stress increases on the outer surface of the clot
exposed to flow. When clotting progresses toward full occlusion, however, the reduction of luminal
cross-sectional area eventually generates a significant pressure drop to reduce flow and wall shear
stress, up to the point of full occlusion [29,30]. At full occlusion, the clot must withstand a pressure
drop across its length (P/L) and this pressure drop drives an interstitial Darcy’s flow of plasma
and blood constituents through the pore space of the clot, generating interstitial stresses.
Intrathrombic hemodynamic force was a potent trigger of NETosis in sterile occlusive thrombi.

2.2 Materials and Methods
2.2.1

Reagents

Reagents were obtained as follows: Alexa Fluor 647 conjugated anti-human CD41 (Bio-Rad,
Raleigh, NC, USA), Anti-human CD18 antibody (clone TS1/18), Anti-human CD11a antibody (clone
HI111), Anti-human CD11b antibody (ICRF44) and PE anti-human CD11a (BioLegend, San Diego,
CA, USA), Sytox-green (Life Technologies, Grand Island, NY, USA), Hoechst 33342 and PE
conjugated anti-human myeloperoxidase (MPO) (Thermo Fisher Scientific, Waltham, MA, USA),
rabbit antibody to histone H3 (Citrulline R2+R8+R17, Abcam, Cambridge, MA, USA), Alexa Fluor
647 goat anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA), fibrillar collagen (type I, Chrono-log, PA,
USA), Dade Innovin lipidated tissue factor (TF, Siemens, Malvern, PA, USA), D-Phe-Pro-Arg-CMK
(PPACK, Santa Cruz Biotechnology, Dallas, TX, USA), corn trypsin inhibitor (CTI, Haematologic
Technologies, Essex Junction, VT, USA), Anti-human CD162 antibody (clone KPL-1; BD
Biosciences, San Jose, CA, USA), Box A from HMGB1 (HMGBiotech, Morrisville, NC, USA),
DNase I recombinant (Roche Diagnostics), Cl-amidine, anti-HMGB1 and anti-RAGE (EMD
Millipore), Convulxin (CVX, Cayman Chemical, Ann Arbor, MI, USA), TRAP-6 trifluoroacetate salt
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(SFLLRN, Bachem Americas, Torrance, CA, USA), Wortmannin (Selleck Chemicals, Houston, TX,
USA), recombinant human P-selectin (Bio-Techne, McKinley Place, NE, USA), methylcellulose,
ethylenediaminetetraacetic acid (EDTA), acetylsalicylic acid (ASA or Aspirin), apyrase and
Sigmacote (Sigma, St. Louis, MO, USA).
2.2.2

Microfluidic assay

For coating collagen or collagen/lipidated tissue factor (TF), a single 1000polydimethylsiloxane (PDMS) patterning device was vacuum-sealed to a Sigmacote-treated glass
slide, as previously described [31,32]. A total of 5 µL of 0.5 mg/mL collagen solution (or collagen
followed by 5 µL infusion of 7 nM TF) was perfused through the channel to create a prothrombotic
coating on the glass. Similarly, 5 µL of 100 µg/ml P-selectin can be used to generate a surface that
allows neutrophil adhesion. The patterning device was replaced by an 8-channel PDMS device with
each channel (40-µm high x 250-µm wide) positioned perpendicular to the patterned collagen (Fig.
2-1). Thrombi were formed under pressure-relief mode [32] for an initial wall shear rate of 100 or
1000 s-1 at a constant withdrawal flowrate of 1 µL/min or 10 µL/min per channel, respectively.

Figure 2-1. Surface patterning device and 8-channel microfluidics assay. Collagen/TF
surfaces were patterned on glass slides using single channel patterning devices (A). Actual
thrombosis experiments were carried out in 8-channel devices (B).

2.2.3

Blood collection and preparation

Whole blood (WB) was collected in 40 µg/mL corn trypsin inhibitor (CTI), 100 µM D-Phe-Pro-ArgCMK (PPACK), or 50 mM ethylenediaminetetraacetic acid (EDTA) from healthy donors who self-
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reported to be free of alcohol and medication for at least 48 hr prior to phlebotomy. All donors
consented under IRB approval (Univ. Penn.) Platelets were labeled with anti-human CD41
antibody, neutrophils were labeled with anti-human CD11a antibody, and DNA was labeled with
Sytox-green (or Hoechst 33342 when indicated).
2.2.4

Flow modes

In the constant-flow mode, clots were allowed to grow in all 8 channels. In the pressure-relief mode,
four alternating channels were loaded with EDTA-treated WB to abolish all clotting. As thrombi
grew in the other four matched channels perfused with FXIIa-inhibited WB (with CTI) or thrombininhibited WB (with PPACK), blood flow was diverted to the EDTA-treated WB channels. The
pressure drop across the occlusive thrombus is a direct metric of momentum dissipation during
permeation which is linked to the shear stresses of the permeating liquid on the internal surfaces
of the porous clot. However, as pressure drop is increased the superficial velocity (and interstitial
shear rates) also increase due to Darcy’s Law. Since neutrophils undergoing shear-induced
NETosis were already entrapped and not moving with high velocity or experiencing high collision
rates or rolling, the shear stress, not the shear rate, of the permeating flow would be the most likely
driver of SINs. Apart from the dynamics of collisions or cell rolling that would correlate with shear
rate, the removal of reactive solutes would also correlate with shear rate. However, enhanced
removal of platelet-derived solutes would not be expected to drive SINs (i.e. isolated neutrophils
do not spontaneously NETose).

The nomenclature can be complicated because the study bridges three important hemodynamic
arenas: (1) the growth of thrombus under flow conditions, (2) the biology of occlusive thrombus
subjected to transthrombus pressure drops, and (3) the microfluidic approaches deployed where
syringe pumps and pressure sensors are used. When a flow rate is set at the pump, the initial wall
shear rate and initial wall shear stress are well defined at the start of the experiment in both the
blood lane and the matched EDTA-blood lane. Once the blood lane becomes fully occluded, the
concept of wall shear rate and wall shear stress now only apply accurately to the EDTA-blood lane,
while the physics of the occluded lane now are dictated by the pressure drop across the clot (Fig.
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2-2) measured with pressure sensors. For full occlusion, the clots are subjected to a pressure drop
created by the paired flowing EDTA-treated lane. The occlusive clots experience interstitial flow
(permeation) that is associated with a superficial velocity (by Darcy’s law). However, the interstitial
shear rates and shear stresses generated within and by this permeating fluid are quite
heterogeneous and difficult to measure directly. Importantly, in all experiments, the syringe pump
flow rate (2 to 20 µL/min per pair of lanes) is what is controlled throughout the experiment. These
syringe pump flow rates correspond, intuitively, to the initial range of venous and arterial wall shear
rates and shear stresses at the start of the experiment before clotting progresses. These syringe
pump flow rates also dictate well defined wall shear rates and wall shear rates in the EDTA-whole
blood lane at times when there is no clotting or when there is full occlusion of the matched lane.
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Figure 2-2. Pout measurement and P across the clot region. The pressures inside the devices
were summarized in the fluidic circuits. The left circuit represents the constant Q mode. It also
represents the beginning phase of the P relief mode when no platelets have accumulated so the
resistances in all eight parallel channels were the same. When 4 of the channels reach occlusion,
the flow rate nearly doubles in the other 4 channels. The differences between the two modes were
used to calculate P across the clots at full occlusion.
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2.2.5

Pressure measurement

Methyl cellulose (0.02%) was added to water to increase the viscosity to that of whole blood (3 cP).
Device exit pressures (Pout) were obtained using ±1, ±5, ±5, and ±15 psi sensors when 3 cP water
was perfused into the devices at 8, 20, 40, and 80 µl/min (Q out), respectively. These flow rates
correspond to 100, 250, 500, and 1000 s -1 (w) in the beginning phase of the pressure relief mode
(at t = 0) when no platelet/fibrin deposition has occurred. Four inlets (each marked with an x in Fig.
2-2) were then blocked to mimic complete channel occlusion, which led to a defined flow rate (Q)
increase in the 4 opened channels. The resistance R in the open channels remained the same
because it is only a function of channel dimension (w, width; h, height; L, length) and fluid viscosity
µ:

𝑅≈

12𝜇𝐿
ℎ
𝑤ℎ3 (1 − 0.63 )
𝑤

(6)

At each wall shear rate, the pressure difference ∆∆P between the two conditions (8 channels vs 4
channels) is a result of the doubled flow rate Q in the 4 open channels:

∆𝑃 = 𝑅𝑄
Pressure drop across the occlusive clots (∆Pclot) was therefore obtained by multiplying ∆∆P by 2.
2.2.6

Imaging

Platelet, neutrophils, and DNA were detected by an epifluorescence microscopy (IX81, Olympus
America Inc., Center Valley, PA, USA) and a CCD camera (Hamamatsu, Bridgewater, NJ, USA).
A 4X objective/0.16NA was used in most of the experiments. A 10X objective/0.30NA was used to
visualize CitH3 and MPO staining. A 20X objective/0.45NA was used to track individual neutrophils’
activities. ImageJ (NIH) was used to analyze acquired images. The mean fluorescent intensity was
measured over the entire collagen patch region. This signal represents total NETs detected per
collagen patch-driven thrombotic occlusion.
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(7)

2.3 Results
2.3.1

Effect of pressure gradient on clot composition

For each pair of microchannels perfused at either 2 or 20 µL/min (Fig. 2-3A, B) to achieve an initial
wall shear rate of 100 or 1000 s-1, respectively, one channel allowed active clotting to proceed to
occlusion and the other matched channel remained fully open during perfusion with EDTA-treated
whole blood. For platelet deposition (no thrombin present with PPACK WB) at an initial wall shear
rate of 100 s-1 (Fig. 2-3A), platelets continually accumulated over the course of the 30 min
experiment with a slow accumulation of neutrophils (~30 neutrophils along the 1-mm long clot)
between 15 and 30 min (Fig. 2-3C, D) and no detection of NETs (Fig. 2-3E, F). In contrast, at an
initial arterial wall shear rate of 1000 s-1, both platelets and neutrophils continually accumulated
(Fig. 2-3C, D), with a marked generation of NETs between 5 and 30 min (Fig. 2-3E, G). NETs were
detected predominately at the distal end of the occlusive clots formed at arterial conditions as well
as interstitial locations where neutrophils became trapped. At occlusion for the arterial pressurerelief condition, a pressure drop per unit length of 163 mm-Hg/mm-clot existed to drive a Darcy flow
through the clot, as determined using measurements with pressure sensors (Fig. 2-2).
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Figure 2-3. Arterial perfusion resulted in NET generation. PPACK WB was perfused over
collagen surfaces at an initial wall shear rate of 100 s -1 (A) or 1000 s-1 (B) under pressure-relief
mode. Platelets (C) rapidly accumulated under both shear conditions. Neutrophil recruitment (D)
progressed after 15 min under venous shear and after 2 min under arterial shear. In contrast to
near-zero baseline level of Sytox-green signal (E) detected at 100 s-1 (F), rapid extracellular DNA
release was observed at 1000 s-1 (G). The endpoint images (t = 30 min) demonstrated that platelet
aggregation was more stable under venous shear whereas arterial shear resulted in non-uniform
thrombus growth and occasional recanalization. (Shaded area: SD; arrows: flow direction).
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2.3.2

Effect of flow rate change on NETosis

The relative lack of neutrophils at the venous condition in Fig. 2-3 may influence the relative lack
of NETs in the clot compared to the arterial condition. To study the effect of hemodynamics on
NETosis at a similar neutrophil density, a perfusion shift-up experiment was conducted where flow
was increased acutely at 15 min from 2 to 20 µL/min per paired channels (Fig. 2-4 A–C). This shiftup increases the P/L across the occluding clot. NETs were detected within 2 min after perfusion
shift-up (Fig. 2-4C). Under conditions where neutrophil density in the clots were similar (Fig. 2-4B),
NETosis was strongly induced immediately after shift-up to the arterial condition, but remained
absent at the venous condition without flow shift-up (Fig. 2-4D vs. Fig. 2-4E). Thus, a strong
temporal coupling of high hemodynamic forces and NETosis was observed with the rapid onset of
NETosis with perfusion shift-up at 15 min.
The NETosis driven by flow shift-up was slowed significantly with perfusion shift-down and then
began once again with a second event of perfusion shift-up (Fig. 2-5 A–C). To further demonstrate
this strong and rapid coupling under full thrombotic conditions (TF present), an increase of
perfusion at either 12 or 18 min also resulted in NETosis within 2 minutes of shift-up (Fig. 2-5 D–
F). This fully demonstrated how rapidly responsive NETosis was to high hemodynamic forces.
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Figure 2-4. Increase from venous to arterial shear triggered NETosis. PPACK WB was used
to first form platelet deposits on collagen patches under venous shear for 15 min. The clots were
then exposed to 1000 s-1 for another 15 min (ΔQ = 2 µL/min  20 µL/min per paired channels).
Although the dynamics of platelet deposition (A) and neutrophil accumulation (B) were similar
between the continual venous shear and the shear rate shift-up conditions, NETs (C) were only
observed immediately after the abrupt shear increase. Furthermore, thrombi formed at 100 s -1 were
able to withstand 15 min of elevated shear stress at 1000 s-1 without recanalization, and NETs were
only observed within the vicinity of the occlusive regions (D, E). (Shaded area: SD).
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Figure 2-5. Hemodynamic forces triggered shear-induced NETosis. The elevated shear stress
was not only required for triggering SIN but also required for the sustained NET release. When the
shear rate was reduced to 100 s-1, extracellular DNA signal started to plateau, and the rapid signal
rise was again observed when the condition was returned to arterial shear (A-C). Flow shift-up (ΔQ
= 2 µL/min  20 µL/min per paired channels) at both 12 min and 18 min led to rapid NET release
within 2 min of the flow rate change (D-F) under conditions of full thrombosis (TF present).
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Shift-up to 500 s-1 (10 µL/min per paired channels) also induced NETosis, while shift-up to 250 s-1
(5 µL/min per paired channels) was insufficient to generate a large enough P/L to drive shearinduced NETs (Fig. 2-6). In a hemodynamic context of 100 s-1 initial shear rate that was not
sufficient to drive NETosis (P/L = 19 mm-Hg/mm-clot), the addition of E. coli to the blood was
sufficient to induce NETs within an occlusive clot. The appearance of NETs due to E. coli (Fig. 27) was slower and less extensive than that observed for conditions of high shear induced NETosis
within sterile occlusive thrombi.

Figure 2-6. Shift-up to 500s-1 resulted in rapid NET release in occlusive thrombi. No significant
differences were seen in platelet/neutrophil deposition (A, B) between 100s-1 and shift-up to 250s1. Only baseline levels of extracellular DNA signals (C) were detected at 30min. In contrast, shiftup to 500s-1 led to slightly more platelet deposition (D), similar neutrophil accumulation (E), but
significantly more DNA release (F). Q = 2  5 µl/min per paired channels for 100 s -1  250 s-1
shift-up at t = 15 min. Q = 2  10 µl/min per paired channels for 100 s-1  500 s-1 shift-up at t =
15 min.
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Figure 2-7. Live E. coli induced NETosis at venous shear rate. The addition of live E.coli to
PPACK WB perfusion over collagen led to increased platelet/neutrophil deposition, and induced
NETosis at 100s-1.
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2.3.3

Effect of thrombin generation on NET release

With no thrombin or fibrin production, continuous arterial perfusion resulted in >150-fold increase
in NET production relative to the venous condition (Fig. 2-8A). NETosis also occurred at arterial
flow conditions or in the perfusion shift-up experiment (Fig. 2-9) when thrombin and fibrin were
allowed to form during sterile thrombosis. Using CTI-treated whole blood perfused over
collagen/tissue factor, a full thrombotic response involving platelet, thrombin, and fibrin
polymerization occurred (Fig. 2-8C, D). With thrombin and fibrin generation, the arterial flow
condition drove NET generation to a level that was >80-fold greater than that of the venous
condition. Similarly, the perfusion shift-up at 15 min resulted in 52-fold and 90-fold increase in NETs
(after 15 min of high flow), relative to no shift-up, in the absence (Fig. 2-8B) or presence of
thrombin/fibrin (Fig. 2-8D), respectively. Neither thrombin nor fibrin was required for shear-induced
NETosis. Additionally, neither thrombin nor fibrin blocked shear-induced NETosis.
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Figure 2-8. Arterial perfusion triggered SIN. In contrast to venous perfusion at 100 s -1, PPACK
WB arterial perfusion at 1000 s-1 (A) resulted in less platelet deposition, more neutrophil
recruitment, and 168-fold higher extracellular DNA signal at t=30min. A ten-fold increase in the
perfusion (B) at 15 min led to similar degree of platelet deposition, fewer adhered neutrophils, but
52-fold more NET signal at the 30-min endpoint. In the presence of thrombin and fibrin (TF present),
mean platelet FIs were similar between 100 s-1 and 1000 s-1 while more neutrophils and
extracellular DNAs were observed in arterial conditions (C). Subjecting thrombin/fibrin-positive
thrombi to shear shift-up caused no significant differences in the number of neutrophils adhered
but 90-fold increase in NET release at 30 min (D). Platelet FI, neutrophil count, and NETs FI were
normalized to each donor’s control. (*, p<0.05; **, p<0.01; ***, p<0.005).
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Figure 2-9. NET release was independent of thrombin generation. In the presence of thrombin
and fibrin polymerization, arterial shear at 1000s-1 (A-C) and a shift-up from 100s-1 to 1000s-1 at 15
min (D-F) both caused substantial amount of NET released.

2.3.4

Surface staining of extracellular DNA

Shear-induced NETs were consistently observed in the distal region of occlusive clots. The NETs
were immunopositive for citrullinated histone H3 (CitH3) and were rapidly degraded by DNase,
confirming that Sytox-green detects NETs under the microfluidic flow conditions of coagulation (Fig.
2-10). Interestingly, not all of the released DNA was immunopositive for CitH3 (Fig. 2-10F)
indicating some heterogeneity in the mechanism of NET release.
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Figure 2-10. Shear-induced NETs were CitH3-positive and DNase-sensitive. CTI WB perfusion
over collagen+TF at 100 s-1 for 15 min resulted in substantial amount of platelet and neutrophil
accumulation and NETosis occurred rapidly after the ten-fold step change in shear (A-D). Blocking
PSGL-1 and CD18 (E) did not prevent either neutrophil recruitment or SIN. Citrullinated Histone H3
(F), a unique marker of NETosis, and MPO (G) were also found to be colocalized with DNA stained
by Hoechst dye. While no change was observed in the channel perfused with HBS (H), treatment
with DNase at 30 min (I) quickly digested the shear-induced NETs.

2.3.5

Effect of antagonists on NET generation

We further tested a number of inhibitors for possible antagonism of shear-induced NETs (Fig. 211). Consistent with the observed physical entrapment of neutrophils in the clotted structures, the
accumulation of neutrophils and the subsequent release of NETs at arterial conditions was not
blocked by anti-PSGL-1 and anti-CD18 despite a delay in neutrophil recruitment (Fig. 2-12).
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Figure 2-11. Inhibitors did not prevent NETosis in thrombin-rich occlusive clots. 500 µM
aspirin, 10 U/ml apyrase, 1 mg/mL BoxA, 10 µg/mL anti-HMGB1, 0.1 mg/mL anti-RAGE, or 100
µM Cl-amidine did not reduce NET release. (n = 2 to 4 clots for each agent tested; NS: not
significant).

Figure 2-12. Blockade of platelet-neutrophil adhesion did not affect NET generation. AntiPSGL1 (A-C) or Anti-CD18 (D-F) alone did not reduce extracellular DNA release. The combination
of the two (G-I) delayed neutrophil accumulation but NETosis was not suppressed. When
combining CD11a/CD11b and CD18 antibodies (Fig. 2-14 A–C), neutrophils still accumulated,
consistent with a physical entrapment mechanism within the platelet mass, and SINs were still
detected. Despite the abundance of platelets in the clot structures, inhibitors against platelet
mediators had little effect on shear-induced NETs. In the presence of thrombin, cyclooxygenase
blockade by aspirin did not affect platelet/neutrophil deposition or NET release.
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When TF was absent on the collagen surface (Fig. 2-13), aspirin caused an expected delay and
reduction in platelet accumulation under flow [33], which consequently delayed the occlusion time
and delayed neutrophil accumulation. At the time of flow shift-up, platelets rapidly accumulated in
the presence of ASA and neutrophil accumulation then progressed along with concomitant shearinduced NETosis when the platelet deposits became occlusive. The recombinant protein reBox A
that blocks subdomain of HMGB1 [6,7] had no effect on the formation of NETs (Figs 2-11, 2-13).
Blocking antibodies against HMGB1 or RAGE had no effect on the extracellular DNA signal.
Inhibiting PAD4 with Cl-amidine [34] did not reduce NET generation (Figs 2-11, 2-13). In the
absence of thrombin/fibrin generation (Fig. 2-14D, F–H), platelet deposition was significantly
reduced, as expected, by the PI3K inhibitor Wortmannin and no neutrophil recruitment occurred.
Without neutrophils, no DNA release was detected. In contrast, when thrombin generation and
fibrin polymerization were triggered with TF (Fig. 2-14E, I–K), platelets accumulated even in the
presence of Wortmannin, neutrophil were captured, and shear induced NETosis was detected.
Under fully thrombotic conditions driven by surface TF where Wortmannin’s effect on platelets was
overcome, the exposure of neutrophils to PI3K inhibition did not block shear-induced NETosis.
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Figure 2-13. Aspirin, Cl-amidine, and HMGB1 antagonists did not impair NET release. When
TF was not coated on collagen surface, 500 µM Aspirin (A-C) changed platelet deposition and
neutrophil accumulation dynamics but rapid DNA release still took place as soon as neutrophils
showed up inside the clots. When collagen/TF surfaces were used, Aspirin (D-F) did not reduce
cellular aggregation or NET generation. Inhibiting histone hypercitrullination by 100 µM Cl-amidine
(G-I) or platelet derived HMGB1 interaction with neutrophil RAGE (J-L) did not shear-induced
NETosis either.

24

Figure 2-14. SIN generation does not require PI3K signaling, CD11a/CD11b, or CD18.
Blocking CD11a/CD11b and CD18 (A-C) did not prevent neutrophil entrapment and NET formation
upon clot occlusion. Wortmannin, a PI3K inhibitor, reduced platelet deposition in the absence of
thrombin generation, and prevented clot occlusion, which in turn abolished neutrophil accumulation
and NET release (D, F-H). However when thrombi occluded the channels in the presence of
thrombin, shear-induced NETosis was not affected (E, I-K).

25

2.3.6

Effect of platelet activation state on shear-induced NETosis

To evaluate if shear induced platelet activation (SIPA) and consequent platelet secretion is driving
shear induced NETosis, we conducted 3 separate experiments (Fig. 2-15) that all demonstrate a
lack of any role for SIPA releasate driving shear induced NETosis: (1) high dose addition of two
major platelet secretagogues (convulxin+SFLLRN) failed to drive NETosis at low shear; (2) high
dose apyrase to target platelet secreted ATP/ADP (the major mediators of SIPA) [35,36] had no
effect on shear induced NETosis; and (3) the effluent from an occlusive clot displaying shear
induced NETosis was directly contacted with a distal monolayer of P-selectin adherent neutrophils
which failed to display any NETosis. While apyrase is the classic approach to block SIPA via ADP
release in closed systems (cone-and-plate viscometry of PRP), apyrase is less effective in dense,
but non-occlusive wall attached platelet deposits that lack significant intrathrombus permeation
[31,37]. In contrast, the pressure-driven permeation of apyrase and ADP is substantially greater for
fully occlusive thrombi compared to non-occlusive thrombi.
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Figure 2-15. Shear-induced NETosis does not require platelet secretion from SIPA. No NETs
were observed in clots formed from blood supplemented with 50 nM Convulxin and 750 µM
SFLLRN on collagen at venous shear (A). High dose apyrase that catalyzes the hydrolysis of
ATP/ADP did not affect shear-induced NETosis (B). When PPACK WB was perfused over collagen
and then P-selectin in a shear shift-up experiment (C-F), similar number of neutrophils accumulated
on both surfaces, but NETs were only generated on collagen.
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2.4 Discussion
Shear-induced NETosis was independent of the coagulation processes of thrombin generation and
fibrin formation. Clot entrapped neutrophils were clearly in close proximity to activated and dense
platelet deposits, however the generation of NETs was largely controlled temporally by the onset
of high hemodynamic forces, consistent with the lack of effect of HMGB1/RAGE and PAD4
inhibitors. Similarly, inhibitors of platelet-neutrophil adhesion did not prevent shear-induced
NETosis. In the assay, neutrophils were observed to haltingly translocate through crevices and
canaliculi of the occlusive thrombi, distinct from classical rolling on inflamed endothelium.
In order to observe neutrophil locations prior to NETosis, we conducted the flow shift-up experiment
at 20X magnification with a 10 sec time interval after the 13 min time point. In Fig. 2-16 B–C, the
highlighted neutrophils showed up before flow shift-up, stayed inside the clot, and released DNA.
The NET releasing neutrophil in Fig. 2-16A arrived at the spot after flow shift-up without DNA signal,
became trapped in the clot, and then released DNA. Therefore neutrophils entrapped under venous
shear were capable of releasing NETs when they were exposed to an elevated pressure drop
across the clot. The physical entrapment of neutrophils could occur both before and after flow shiftup and neutrophils may also translocate through the thrombus after shift-up to deliver neutrophils
to entrapped positions that then facilitate shear-induced NETosis. Since neutrophils undergoing
shear-induced NETosis were already entrapped and not moving with high velocity or experiencing
high collision rates or rolling, the shear stress, not the shear rate, of the permeating flow would be
the most likely driver of SINs.
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Figure 2-16. Entrapped neutrophil released DNA at arterial shear. Individual neutrophil
activities were tracked at 20X magnification. Highlighted neutrophils became entrapped inside the
clot before (B, C) and after (A) flow shift-up, and released DNA under arterial pressure drop.

In static incubation assays utilizing platelet activating factor, ionomycin, or phorbol ester and lasting
several hours, platelet P-selectin was found to promote NETosis [38]. Other studies using both
static and flow assays, however, found platelet P-selectin was not required for NETosis driven by
LPS for 60 min [39] or driven by activated platelets releasing HMGB1 [6]. During microfluidic
clotting, we observed that PSGL-1 and CD18 blocking antibodies used together impaired the
platelet-neutrophil interactions as demonstrated by the modest delay in neutrophil accumulation,
however, physically entrapped neutrophils still released extracellular DNA at the onset of high shear
stress. Also, ASA has been reported to reduce NETosis during TRALI [20] or experimental
peritonitis [40]. However, neutrophil response to platelet derived thromboxane is not well defined

29

(absent the thromboxane receptor) and ASA may have direct effects on neutrophils via COX2dependent PGE2 production [41] that may inhibit NETosis to some extent [42]. We found that
thromboxane antagonism with ASA reduced platelet accumulation and subsequent occlusion, but
ultimately did not prevent shear-induced NETs. In addition, we conclude that shear-induced NET
production appears to be a process that does not require paracrine signals from shear induced
platelet activation (SIPA) during sterile thrombosis.
In these microfluidic experiments, the essential hemodynamic condition to drive SINs was a P/L
of ~ 87 to 163 mm-Hg/mm-clot (Fig. 2-2) across the occlusive clot. In humans, a 0.1 mm-long
occlusive clot within an arteriole would experience P/L ~ (70 – 30 mm-Hg)/0.1 mm-clot = 400
mm-Hg/mm-clot as the blood distal of the clot depressurizes to the capillary inlet pressure. We
conclude that sterile arteriole occlusions during DIC experience hemodynamics forces sufficient to
drive shear-induced NETs. Interestingly, patients with sepsis display elevated plasma level of NETs
if they also experience DIC [17]. Our results indicate that arteriole thrombosis can generate NETs
as a result of intrathrombus hemodynamic shear forces. Additionally, we hypothesize that
thrombotic occlusions between the arterial and venous system (AV fistula) may be potentially
susceptible to large intrathrombic forces that render the occlusion especially prone to shear induced
NETosis.
During hemostasis, sterile hemostatic clots within a punctured arteriole or artery wall connect the
arterial blood compartment pressure (70 to 120 mm-Hg) to an interstitial pressure compartment (5
- 10 mm-Hg) or to the atmosphere (0 mm-Hg). Such hemostatic clots experience a P/L ranging
from 60 to 1200 mm-Hg/mm-clot for clots that are 0.1 to 1 mm in dimension between compartments.
An occlusive hemostatic clot at the end of a fully severed arteriole would experience a similar range
of P/L, depending on length. In the context of hemostatic clots, shear-induced NETs might
represent an anti-microbial barrier on the outer surface of the clot facing contamination during
wounding. In the context of internal intrathoracic injury, the possibility of subatmospheric interstitial
pressures (-10 mm-Hg) via diaphragm mechanics would further increase pressure drops across
the hemostatic clots sealing injured vessels.
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NETs have been recently identified within coronary thrombi [16]. Mangold et al. reported that
coronary thrombi contained significantly more NETs than venous thrombi, and they observed no
NETs in clot formed in vitro under static conditions. While other factors such as cholesterol crystals
could also play a role, it is possible that shear stress may contribute to the higher NET level found
in coronary thrombi. A small occlusive thrombus (L = 1 mm in length) within a stenosed artery would
experience peak P/L ~ 100 mm-Hg/mm-clot, sufficient to drive shear-induced NETs, assuming
distal capillary flow stops and depressurizes to the venous pressure (10 mm-Hg). In contrast, partial
coronary occlusions may experience little interstitial permeation, but would experience
pathologically high wall shear stresses on their outer boundary exposed to flow, a driving force for
von Willebrand Factor unfolding [30]. Furthermore, the rapid shear-induced NET release implies
the possibility that hemodynamic forces may become an important mediator of neutrophil
extracellular DNA as thrombosis approaches the instant of full vessel occlusion. Because
hemodynamic forces are driven by P/L across a clot, extreme hypertension might exacerbate
shear-induced NETosis following sterile thrombotic occlusion.
Venous clots that are many centimeters in length likely have minimal interstitial flow to drive shearinduced NETosis. While DVT occurs in the setting of low flow or stasis and can present NETs [15],
the final DVT in patients results in arterial pressures upstream of the clot (and consequent extreme
venous dilation, the radiological signature of DVT) and venous pressures downstream of the clot.
A pressure drop of ~100 mm-Hg over an initiating venous clot length of 1 mm might create
substantial interstitial shear stress due to permeation. However, the size of the venous valve pocket
would suggest that an occluding venous clot would have to be several millimeters in length with a
pressure drop less than what was found necessary to drive shear-induced NETs.
The flow upshift experiment resulted in rapid NETosis within 2 min. In contrast, pathogens have
been shown to induce vital NETosis within an hour [43] and incubation of neutrophils in vitro with
50 nM PMA or 20 ng/mL TNF requires 180 min for suicidal NET generation [40]. A variety of poreforming cytolytic toxins have also been reported to induce NET generation [44,45]. This suggests
shear-induced formation of membrane pores may be sufficient to trigger NETosis. Indeed,
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Malachowa et al [45] reported that neutrophils exposed to electroporation release diffuse DNA that
resembles PMA-induced NET structures. While electroporation is not physiological, our results
demonstrate that fluid shear stress and large membrane stresses may render neutrophils
vulnerable to membrane disruption and NETosis. By simulation of flow in dense clots, we calculate
that hemodynamic forces on neutrophils in clots can substantially exceed the shear stress lysis
threshold of 15 Pa needed to drive neutrophil lysis in a cone-and-plate viscometer.
2.5 Conclusions
To our knowledge, this is the first report of hemodynamic forces driving rapid NETosis within
sterile occlusive thrombi. NETs generated in response to pathophysiological hemodynamic stress
might have thrombotic or inflammatory properties similar to NETs triggered by other stimuli. The
role of shear-induced NETs in the context of sickle cell crisis and other schistocyte-positive
microangiopathies [46] remains to be explored.
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Chapter 3: Fibrin modulates shear-induced NETosis
3.1 Introduction
NETs have been found in sepsis, venous and arterial thrombosis, disseminated intravascular
coagulation (DIC), and trauma-induced coagulopathy (TIC) [7,15–17,47–51]. In these diseases,
NETs can provide physical scaffolds for clot growth by catching platelets, erythrocytes, fibrin, and
von Willebrand factor [52,53]. Individual NET components may also contribute to thrombus
formation through their interaction with the coagulation pathway. DNA and histone have been
reported to activate factor XII and amplify tissue factor (TF)-dependent thrombin generation [54].
Neutrophil elastase and myeloperoxidase can inactivate tissue factor pathway inhibitor and
thrombomodulin. However, intact NETs may behave differently from DNA or purified histone
proteins [9].
NETs and their individual components also modulate clot lysis. In a plasma environment, DNA and
histones increase fibrin fiber diameter, stability, rigidity and permeability [55,56]. Histones have
been shown to delay clot lysis, and the combination with DNA further prolongs lysis time [55].
Histones also inhibit thrombin inactivation by antithrombin, and DNA reduces plasminogen
activation on plasma clots [56]. NETs can also inhibit fibrinolysis by promoting tPA inactivation by
PAI-1, and potentiate fibrinolysis by stimulating fibrin-independent plasminogen activation [57].
DNase accelerated tPA-induced lysis in clots obtained from acute ischemic stroke and acute
coronary syndrome patients [16,58].
We have previously showed that large intrathrombus hemodynamic forces driven by transthrombus
pressure drop (∆P/L > 70 mm Hg/mm-clot) trigger rapid NET release within sterile occlusive clots
[59]. Shear-induced NETs are DNase I sensitive and stain positive for common NET markers such
as myeloperoxidase and citrullinated histones. Shear induced NETosis (SIN) can occur with or
without thrombin/fibrin. How and whether fibrin generation or fibrinolysis influence NET production
still remains unclear.
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To investigate the effect of fibrin polymerization/dissolution on NETosis, NET production was
measured in clots with varying amount of fibrin. Whole blood was perfused over prothrombotic
surfaces in microfluidic channels to deposit platelet/fibrin mass. The degree of fibrin accumulation
was controlled through changing the dosage of tPA, ACA or Gly-Pro-Arg-Pro (GPRP). At
occlusion, clots can be viewed as a porous media, through which the transport of soluble and
insoluble blood constituents is driven by the prevailing pressure drop (P/L). Blood cells can
become physically trapped and migrate locally within clots. Large pressure gradients can result in
high interstitial fluid shear stress and high membrane stress [59], which then lead to SIN. In this
study, we found that the extent of shear-induced NET release is inversely correlated with the
amount of fibrin in occlusive clots in vitro. Furthermore, a fibrin network reduces NETs within
thrombi at high P/L. Conversely, fibrinolysis or GPRP enhances SIN when P/L is high.
3.2 Materials and Methods
3.2.1

Materials

Reagents were obtained as follows: Alexa Fluor (AF) 647 conjugated anti-human CD41 (Bio-Rad,
Raleigh, NC, USA), Anti-human CD18 antibody (clone TS1/18), PE anti-human CD11a
(BioLegend, San Diego, CA, USA), AF647 conjugated human fibrinogen (ThermoFisher Scientific,
Grand Island, NY, USA), Sytox-green (Life Technologies, Grand Island, NY, USA), fibrillar collagen
(type I, Chrono-log, PA, USA), Dade Innovin lipidated tissue factor (TF, Siemens, Malvern, PA,
USA), D-Phe-Pro-Arg-CMK (PPACK, Santa Cruz Biotechnology, Dallas, TX, USA), corn trypsin
inhibitor (CTI, Haematologic Technologies, Essex Junction, VT, USA), tPA (Abcam, Cambridge,
MA, USA), H-Gly-Pro-Arg-Pro-OH acetate salt (GPRP, Bachem Americas, Torrance, CA, USA), aminocaproic acid (ACA), ethylenediaminetetraacetic acid (EDTA), and Sigmacote (Sigma, St.
Louis, MO, USA).
3.2.2

Surface patterning

For coating collagen or collagen/lipidated tissue factor (TF), a single 1000-µm wide channel
polydimethylsiloxane (PDMS) patterning device was vacuum-sealed to a Sigmacote-treated glass
slide, as previously described [31,32]. A total of 5 µL collagen solution (or collagen followed by 5

34

µL infusion of 20 nM TF) was perfused through the channel to create a prothrombotic surface trigger
on the glass. The patterning device was then replaced by an 8-channel PDMS device. The 8 parallel
channels were positioned perpendicular to the patterned collagen to form 8 uniformly distributed
prothrombotic patches (250 µm wide x 1000 µm long).
3.2.3

Blood collection and preparation

Whole blood (WB) was collected in 40 µg/mL corn trypsin inhibitor (high CTI or HCTI), 4 µg/mL CTI
(low CTI or LCTI), 100 µM D-Phe-Pro-Arg-CMK (PPACK), or 50 mM ethylenediaminetetraacetic
acid (EDTA) from healthy donors who self-reported to be free of alcohol and medication for at least
48 hr prior to phlebotomy. All donors consented under IRB approval (Univ. Penn.) Platelets were
labeled with anti-human CD41 antibody, neutrophils were labeled with anti-human CD11a antibody,
and DNA was labeled with Sytox-green (or Hoechst 33342 when indicated). AF647 conjugated
fibrinogen was added to blood to monitor thrombin/fibrin generation.
Thrombi were formed under pressure-relief (P relief) mode at a constant withdrawal flowrate of 2
µL/min or 20 µL/min per pair of channels, respectively. EDTA was added to blood to abolish clotting
in four alternating channels. As thrombi grew in the other four matched channels perfused with
FXIIa-inhibited WB (with CTI) or thrombin-inhibited WB (with PPACK), flow was diverted to the
EDTA-treated WB channels. At channel occlusion, pressure drops across the clots have been
measured to be 19 mm Hg/mm for venous perfusion and 163 mm Hg/mm for arterial perfusion.
A fixed device outlet flowrate sets a well-defined initial venous or arterial wall shear rate. As a clot
continues to grow and occupy the luminal space of a microfluidic channel, the flow-facing side of
the thrombus experiences increased fluid shear rate and shear stress. Upon occlusion, the
pressure drop regulated by the paired flowing EDTA-blood lane drives a Darcy’s flow (permeation)
of solutes and blood cells through the porous clot. The rate of this interstitial flow (or the superficial
velocity) is influenced by the clot permeability, which can vary significantly depending on the clot
composition. The transthrombus pressure drop also generates intrathrombus hemodynamic shear
stresses on the physically entrapped neutrophils and dictates the extent of shear-induced NETosis.
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3.2.4

Imaging

Platelets, fibrin, neutrophils, and extracellular DNA were detected by an epifluorescence
microscopy (IX81, Olympus America Inc., Center Valley, PA, USA) and a CCD camera
(Hamamatsu, Bridgewater, NJ, USA). A 4X objective/0.16NA was used in the experiments. ImageJ
(NIH) was used to analyze acquired images. The mean fluorescent intensity was measured over
the entire collagen patch region. This signal represents total NETs detected per collagen patchdriven thrombotic occlusion.
3.3 Results
3.3.1

Effect of thrombin inhibition

Whole blood (WB) treated with 100 µM PPACK was perfused over collagen surfaces to deposit
platelets. Minimal fibrin(ogen) was detected as the concentration of PPACK used was enough to
inhibit the majority of the thrombin generated (Fig. 3-1A). We also perfused CTI-treated (40 µg/ml)
WB over collagen+TF surfaces to enable a full thrombotic response involving platelet accumulation,
thrombin generation, and fibrin deposition. After 30 min perfusion under arterial pressure drops,
fewer neutrophils accumulated when thrombin/fibrin generation was present (Fig. 3-1B). The
difference was non-significant under venous conditions. Minimal levels of extracellular DNA signal
were detected during venous perfusion (± thrombin/fibrin) and no significant differences were seen
between the near-zero DNA content of thrombin-poor and thrombin-rich clots (Fig. 3-1C, D). In
contrast, the presence of thrombin/fibrin generation resulted in a 6-fold reduction to the NET
production under arterial pressure drops. Total NET generation was normalized to the number of
neutrophils within clots (DNA:Neutrophil) to measure the extent of NETosis on a per neutrophil
basis. The results showed that essentially no neutrophils formed NETs under venous flow, thus the
presence/absence of thrombin did not make a difference (Fig. 3-1D). In contrast, substantial
amount of NETs were observed at arterial pressure drop and thrombin production significantly
reduced normalized NET generation. Therefore, thrombin/fibrin generation reduced the extent of
NETosis during arterial clot formation, as measured by total DNA or by total DNA/neutrophils.
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Figure 3-1. Thrombin and fibrin generation suppressed NET release after 30 min of arterial
perfusion. PPACK WB was perfused over collagen surfaces (, thrombin/fibrin-) and CTI WB was
perfused over collagen+TF surfaces (, thrombin/fibrin+) under both venous and arterial pressure
drops. Fibrin polymerization occurred (A) in thrombin-rich clots but not in thrombin-inhibited clots.
Neutrophil accumulation (B), NET generation (C), and DNA:Neutrophil ratio (D) were significantly
reduced in the presence of thrombin under arterial conditions. No significant differences were
observed under venous conditions. (Venous: P/L=19 mm Hg/mm-clot; arterial: P/L = 163
mmHg/mm-clot; n.s.; not significant; *: p<0.05; **: p<0.005).

3.3.2

Effect of fibrinolysis on shear-induced NETosis

At high P/L, thrombin and/or fibrin inhibition could have contributed to the reduction in NET
production (Fig. 3-1C-D). To help explore the role of fibrin, whole blood was treated with different
concentrations of exogenous tPA and perfused over collagen+TF surfaces under arterial pressure
drops. After 15 min (Fig. 3-2A) of clot growth, tPA resulted in a dose-dependent lysis of fibrin.
Whereas thrombi composition was unaltered in the presence of low dose tPA (3 nM), higher doses
almost completely dissolved the fibrin network within 30 min (Fig. 3-2B). With or without added
tPA, platelets (Fig. 3-2C) rapidly accumulated and occluded channels. In the presence of medium
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doses of tPA (15 nM), enhanced fibrinolysis led to slower net fibrin deposition initially. The rate of
fibrinolysis exceeded fibrin polymerization rate after 18 min and clots started experiencing net fibrin
loss (Fig. 3-2D). At high doses of tPA (30 nM), fibrin deposition rate was similar to what we
observed at 15 nM tPA early on, and fibrin content reached a lower peak value at an earlier time
point (9min). Most importantly, the medium and high doses of tPA both caused a 2.5 fold increase
in NET production (Fig. 3-2B, E).

Figure 3-2. Tissue type plasminogen activator dose dependently lysed fibrin clots and
promoted NETosis. CTI treated whole blood dosed with different concentrations of tPA were
perfused over collagen+TF surfaces under constant arterial pressure drops to form clots with
varying degree of fibrin. Dose dependent increase in fibrin degradation was evident after 15 min of
perfusion (A). At 30 min (B), both 15 nM and 30 nM tPA almost completely removed fibrin network.
Platelet deposition (C) was similar among all clots regardless of the different fibrin growth dynamics
(D). Medium and high doses of tPA that were sufficient for fibrin degradation also resulted in
enhanced NET generation. (Shaded area: SD; arrows: flow direction).
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Because tPA has been previously reported to cause neutrophil degranulation [60], we also
evaluated its potential to directly induce NETosis. Clots were formed in the presence/absence of
30 nM tPA under venous shear. Low concentrations of CTI (4 µg/ml) was used to reduce any nonspecific effects of CTI on tPA [61]. Early on (<7.5 min), clots formed from blood with/without added
tPA were indistinguishable in terms of fibrin accumulation (Fig. 3-3A). Fibrin content then started
to decrease in tPA-treated clots, but continued to increase in the absence of added tPA. Neutrophil
accumulation reached the maximum approximately at 7.5 min and stayed relatively constant for
the remaining time of the experiments (Fig. 3-3B). With or without tPA, only near-zero baseline
levels of extracellular DNA signal (Fig. 3-3C) and DNA:Neutrophil ratio (Fig. 3-3D) were detected
at low P/L. This demonstrated that tPA and/or plasmin, on their own, do not trigger NETosis.
Rather, the NET-promoting effect of tPA and fibrinolysis was shear-dependent.
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Figure 3-3. Tissue type plasminogen activator is not a direct NET inducer under venous flow.
In the presence of low level CTI, 30 nM tPA was still enough to completely remove fibrin (A) after
45 min of perfusion under venous conditions. The presence of tPA did not alter the trend in
neutrophil accumulation (B), NET release (C), or DNA:Neutrophil ratio (D).
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During arterial perfusion, fibrin accumulation (Fig. 3-4A) continued to rise in the tPA-free channels.
Similar to the venous condition, treatment with 30 nM tPA was enough to cause net fibrin loss in
the presence of 4 µg/ml CTI. The number of neutrophils reached the peak around 15 min within
fibrin-rich clots (no tPA added). In contrast, neutrophil deposition kept increasing in tPA-treated
clots likely due to the increased porosity with ongoing fibrinolysis (Fig. 3-4B). Extracellular DNA
production continued to grow both in the presence and absence of added tPA (Fig. 3-4C), but the
slope was steeper when fibrinolysis occurred. Whereas NET generation started to slow down in
fibrin-rich clots, it actually accelerated in tPA-treated clots at later time points. DNA:Neutrophil ratios
were similar between the two conditions early on but diverged after 15 min of arterial perfusion
(Fig. 3-4D). In the absence of added tPA, the ratio started to plateau as both neutrophil
accumulation and DNA release began to slow down. In tPA-treated clots, NET generation was
faster than neutrophil accumulation as the percentage of neutrophils undergoing NETosis
continued to rise.

41

Figure 3-4. Tissue type plasminogen activator promoted NETs per neutrophil at arterial
pressure drop. In the presence of low level CTI, 30 nM tPA was sufficient for complete fibrin
degradation (A) under arterial pressure drops as well. Neutrophil deposition (B) slowed down in
untreated clots, but continued to rise in tPA-treated clots. NET generation (C) was significantly
faster in tPA-treated clots at later time points. After normalizing total NET generation to neutrophil
accumulation, the NET generation per neutrophil (D) was still greater with tPA present.

In both venous and arterial perfusions, 30 nM tPA was sufficient to dissolve fibrin (Fig. 3-5A) and
the differences in neutrophil accumulation were non-significant between the control and tPA
conditions at the end time point (45 min). In contrast to clots formed under venous shear, which
contained similar levels of NETs (Fig. 3-5C, E) with/without tPA, clots formed under arterial shear
had a 3-fold increase in total NET generation when tPA was present (Fig. 3-5C, F). Under arterial
pressure drops, tPA also caused a 2-fold increase in DNA:Neutrophil ratio (Fig. 3-5D, E). The
difference was non-significant under venous shear (Fig. 3-5D, F).
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Figure 3-5. The effects of tPA on clot composition mimicked the effects of PPACK. 30 nM
tPA eliminated essentially all fibrin (A) under both venous and arterial pressure drops. Neutrophil
accumulation (B) was not significantly different between tPA-treated and untreated clots,
regardless of the shear conditions. Extracellular DNA release (C) and normalized NET level (D)
were similar between fibrin-rich and fibrin-depleted clots under venous flow, whereas a significant
increase was observed in both measurements in the presence of tPA. The plasminogen activator
did not significantly alter clot composition except the fibrin content under venous pressure drops
(E). In contrast, the fibrinolytic agent caused a 3-fold reduction to total NET production and a 2-fold
reduction to normalized NET generation under arterial pressure drops (F). (n≥6 clots. n.s.; not
significant; *: p<0.05; **: p<0.005).

Because tPA only promoted NET formation in clots with ongoing fibrinolysis, we hypothesized that
fibrinolysis may be responsible for the enhanced NET production. However, tPA may also promote
NET generation through other mechanisms. To test this, we added the inhibitor ACA to tPA-treated
blood. ACA blocked fibrin degradation and reduced NET generation to the tPA-free level (Fig. 36). We also tested tPA in arterial clots formed with PPACK treated blood, and it did cause any
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significant differences in NET generation (Fig. 3-7). Therefore, fibrinolysis was indispensable for
the NET-enhancing effect of tPA. A closer look also revealed that NETs formed in fibrin-rich clots
were mostly retained in their original position, whereas NETs inside fibrin-poor thrombi translocated
through clots in the direction of flow. Fibrin network is known to stabilize platelet aggregation and
decrease clot permeability. The perceived motion of NETs was likely a result of increased thrombus
porosity upon fibrinolysis.
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Figure 3-6: Fibrinolysis is indispensable for the NET-promoting effect of tPA. The addition of
-aminocaproic acid (ACA) to tPA-treated blood restored fibrin deposition (A) to the control level.
Neutrophil accumulation (B) and total NET generation (C) were elevated when both tPA and ACA
were present but not as much compared to clots treated with tPA alone. Normalized NET
generation (D) in tPA-treated clots was twice as high as the level in control and combo-treated
clots.
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Figure 3-7: GPRP and tPA do not affect shear-induced NETosis in the absence of thrombin
under arterial pressure drops. After 45 min arterial perfusion of PPACK WB over collagen
surfaces with or without tPA/GPRP, no differences were observed among the three conditions in
either NET or NET/neutrophil signals.

3.3.3

Effect of inhibiting fibrin polymerization

When we treated blood with GPRP to inhibit fibrin polymerization while still preserving thrombin
generation, a similar increase in NET production was observed. In contrast, adding GPRP to arterial
clots formed with PPACK treated blood did not affect NET generation (Fig. 3-7). As shown in Fig.
3-8A, fibrin was not made throughout the experiment with GPRP present. GPRP also resulted in
an upward trend in neutrophil deposition and NET generation (Fig. 3-8B, C) presumably due to
increases in clot permeability and blood constituent influx. Most importantly, there was a 2.5-fold
increase in the normalized NET level (DNA:neutrophil) when fibrin polymerization was inhibited
with GPRP (Fig. 3-8D).
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Figure 3-8. Blocking fibrin polymerization also promoted shear-induced NETosis at arterial
pressure drop. GPRP completely abolished fibrin polymerization (A) and resulted in an upward
trend of neutrophil accumulation, similar to the one for tPA-treated clots. The presence of GPRP
led to even higher levels of total NET generation (C) and NET:Neutrophil ratio (D) compared to
tPA-treated clots.

3.3.4

Correlation between fibrin content and SIN

Because the effects of tPA on fibrin deposition, neutrophil accumulation, and NET generation
almost completely matched the effects of PPACK, we hypothesized the fibrin mass alone was a
good predictor of the amount of NETs generated at arterial P/L. Therefore, we plotted DNA and
DNA:Neutrophil after 30 minutes of arterial perfusion as functions of clot fibrin content (Fig. 3-9A,
B). Clots treated with GPRP and PPACK had minimal fibrin accumulation and highest NET
generation. Intermediate levels of fibrin deposition and NET generation were seen in tPA-treated
clots at 30 min. Clots made with LCTI/HCTI-treated blood or clots formed in the presence of tPAACA combo had most abundant fibrin and least amount of NETs. Both total NET generation
(r2=0.858) and normalized NET generation (r2=0.9817) were inversely correlated with fibrin under
6 different pharmacological conditions.
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Figure 3-9. Fibrin modulates the extent of NETosis within platelet-rich clots. After 30 min of
arterial perfusions, Total NET production (A) and normalized NET generation (B) both showed a
strong inverse correlation with the level of fibrin deposition across different conditions.

3.4 Discussion
Physically entrapped neutrophils can undergo shear-induced NETosis when occlusive thrombi
experience >70 mmHg/mm-clot [59]. Such phenomena could potentially take place in coronary
arterial thrombosis and ischemic strokes, where NETs have been identified in patient thrombus
samples [16,58]. Previously we have shown the production of NETs does not require thrombin
generation. This is in line with a recent study in which the authors reported that NETs could form
in chronic neutrophilia in mice treated with Dabigatran, a thrombin inhibitor [62]. Here we showed
that the formation of shear-induced NETs was actually increased in sterile occlusive thrombi when
thrombin generation was inhibited. Forming clots in the presence of high dose exogenous tPA
resulted in a similar increase in NET production. Furthermore, the rise in the percentage of
NETosing neutrophils was responsible for this increase. Because tPA is known to cause neutrophil
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degranulation [60], we also examined the possibility of tPA being a direct NET inducer. In contrast
to the accelerated NET formation under arterial pressure drop, no significant difference was
observed between the fibrin-rich and tPA-treated clots under venous flow. Therefore, tPA does not
directly trigger NETosis; instead tPA removes fibrin which then facilitates shear-induced NET
formation. Because inhibiting plasminogen activation and plasmin with ACA abolished the NETpromoting effect of tPA, the modulation of NETosis by tPA must rely on fibrinolysis. The enhanced
shear-induced NETosis is likely a result of increased clot porosity and enhanced exposure to shear
forces when fibrin is removed or absent. It is well established that fibrin network modulates clot
permeability, which can increase substantially as fibrin volume fraction decreases in a platelet-rich
clot [63]. Under the same pressure drop, increased permeability translates to enhanced flow,
stresses, and transport. While the neutrophil influx was likely higher as well in fibrin-poor clots,
normalized NET generation was also higher on a per neutrophil basis. Similar to tPA, the use of
GPRP helped us decouple effects of thrombin generation and fibrin deposition on SIN. Fibrin
polymerization was absent within GPRP-treated clots while thrombin generation was left intact.
Consistent with the NET-promoting effect of tPA, GPRP also led to enhanced NET generation and
a higher DNA:Neutrophil ratio. Together, the aforementioned results suggest a SIN-suppressing
role of fibrin.
While NETosis may provide evolutionary advantages of trapping and killing bacteria in infectious
diseases [4], they appear to do more harm in sterile inflammation and thrombosis [23]. Therefore,
the NET-suppressing/sequestering property of fibrin is beneficial as it protects neutrophils (and
potentially other blood cells) from large interstitial shear stresses within occlusive thrombi and
allows them to proceed with their normal functions.
NETs have been previously shown to act as a platelet/erythrocyte-immobilizing scaffold that is
sufficient for vascular occlusion in DNase-deficient mice stimulated with granulocyte colonystimulating factor [62]. NETs can also hinder thrombolysis [16,55,56,58] and contribute to
ischemia/reperfusion injuries [64]. For those reasons, the DNase/tPA combo proposed by other
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groups [58,64] is promising as it may facilitate NET digestion and clot resolution during thrombolytic
therapies.
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3.5 Conclusions
In this study, we demonstrated that the extent of shear-induced NETosis is inversely correlated
with the amount of fibrin in occlusive platelet-rich clots. Whereas fibrin suppresses shear-induced
NETosis and sequesters NETs within clots, fibrinolytic agents promote shear-induced NETosis.
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Chapter 4: Hemophilia assays
4.1 Introduction
Congenital hemophilia is a genetic disorder that increases bleeding risk in affected individuals. The
two major types of the bleeding disorder are hemophilia A (HA) with a deficiency in coagulation
factor VIII (FVIII) and hemophilia B (HB) with a deficiency in factor IX (FIX) [65]. In healthy subjects,
FVIIIa (activated FVIII) acts as a cofactor for FIXa, serving to increase the affinity of FIXa by 10,000fold. FIXa then converts FX to FXa. Both FVIII and FIX are parts of the intrinsic pathway of
coagulation, which is impaired in hemophilia patients. Based on the residual factor levels, the
bleeding disorder can be categorized into severe (<1% residual factor activity), mild (1-5%) and
moderate (5-40%). However, while residual FVIII activity is useful for the stratification of patients,
the bleeding risk amongst these groups can vary considerably and is influenced by multiple factors
such as genetic mutation types or von Willebrand factor levels [66–69]. Individuals with hemophilia
A or B are more likely to have bleeding in the joints where TF expression is considered low and
biomechanical perturbation is high.

Hemophilia patients have been traditionally treated with intravenous factor replacement therapies
to restore their residual factor levels for prophylaxis. If patients develop neutralizing antibodies
against FVIII or FIX, they can be treated with bypassing agents such as activated prothrombin
complex concentrates (aPCC) or recombinant FVIIa (rFVIIa) [70,71].

rFVIIa enhances FX

activation through TF-dependent, cellular surface-dependent, and EPCR-dependent pathways
[72]. A recent advance is the development of a bispecific antibody (emicizumab), which mimics
FVIIIa function [73,74] by transiently binding FIXa and its substrate FX to mediate FXa generation.
Emicizumab is advantageous in that it can be subcutaneously administered and has a long halflife (4 weeks). More importantly, the bispecific antibody can be used in patients with and without
FVIII inhibitors. In addition to the traditional bypassing agents and FVIIIa-mimicking bispecfic
antibodies, several other novel agents are being investigated. For example, three monoclonal
antibodies against TFPI are currently in different phases of development [75].
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The determination of residual FVIII/FIX activity is assessed in the clinic using a static assay that
uses plasma rather than whole blood. Microfluidic assays allow the phenotyping of whole blood
from hemophilia patients and an assessment of efficacy of various hemophilic therapeutics under
flow [76–82]. In such assays, whole blood is perfused over prothrombotic surfaces such as collagen
or collagen/TF and clot growth is measured. Blood from severe hemophilia patients displays a
defect in both platelet deposition and fibrin formation under flow. In contrast, blood from moderate
and mild hemophilia patients displays relatively normal platelet deposition with deficits in fibrin
formation.

Patient recruitment, variability in their clinical presentation, and interference from

prophylactic products all pose significant challenges to the development of whole blood microfluidic
assays to study drug potency or mechanism of action on a background of hemophilia. Therefore, it
would be useful to recapitulate the hemophilic phenotypes ex vivo using treated blood from healthy
donors. Such hemophilia models then allow significantly greater throughput and standardization
compared to using blood from patients with hemophilia. Donated healthy blood is more readily
available and excludes the potential interference from other drugs. We present two hemophilia
microfluidic assays using healthy adult blood to study the effect of bypassing agents. The use of
highly diluted TF or FXIa in the triggering surface allowed the dose-response testing of anti-TFPI,
rFVIIa, emicizumab, as well as a patient-derived FVIII-neutralizing antibody.
4.2 Materials and Methods
4.2.1

Materials

Reagents were obtained as follows: Alexa Fluor 488 conjugated anti-human CD61 (Bio-Rad,
Raleigh, NC, USA), AF647 conjugated human fibrinogen (ThermoFisher Scientific, Grand Island,
NY, USA), type I fibrillar collagen (Chrono-log, PA, USA), Dade Innovin lipidated tissue factor (TF,
Siemens, Malvern, PA, USA), corn trypsin inhibitor (CTI) and Factor XIa (Haematologic
Technologies, Essex Junction, VT, USA), HEPES (Fisher Scientific, Hampton, NH), Sigmacote
(Sigma, St. Louis, MO, USA), Anti-FVIII (4A4, Green Mountain Antibodies, Burlington, VT, USA),
Anti-TFPI (gA200 hlgG1, Bayer, Whippany, NJ, USA), bispecific antibody (emicizumab), rFVIIa
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(NovoSeven), reFIX-V181T variant [83], and a recombinant rIgG4 containing CDRs originally
derived from a patient (NB41, as described in [84]).
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4.2.2

Surface patterning

A single 250 µm-wide channel polydimethylsiloxane (PDMS) patterning device was vacuum-sealed
to a Sigmacote-treated glass slide, as previously described [31,32]. A total of 5 µl of fibrillar collagen
was perfused through the channel to pattern a stripe of aligned collagen fibers. For TF-dependent
assays, this step was followed by TF perfusion (20 nM or 1 nM, 5 µl) and incubated under static
conditions for 30 min to allow binding to collagen. For intrinsic-pathway dependent assays, FXIa
(4.9 µg/ml, 5 µl) was used instead of TF. The channel was then rinsed with 20 µl of 1% bovine
serum albumin. The patterning device was then replaced by an 8-channel PDMS device positioned
perpendicularly to the surface pattern stripe to form 8 uniformly distributed prothrombotic patches
(250 µm x 250 µm).

4.2.3

Blood collection and preparation

Whole blood (1 ml) was collected into a syringe containing corn trypsin inhibitor (CTI, 4 µg/ml) to
lightly suppress contact pathway activation of FXIIa during sample collection and handling. Whole
blood was subjected to microfluidic assay within 10 min of collection.
4.2.4

Imaging

Platelet and fibrin were detected by an epifluorescence microscopy (IX81, Olympus America Inc.,
Center Valley, PA, USA) and a CCD camera (Hamamatsu, Bridgewater, NJ, USA). A 10X
objective/0.30NA was used in all of the experiments. ImageJ (NIH) was used to analyze acquired
images. The mean fluorescent intensity was measured over the central 75% of the channel to
eliminate side-wall effects. The fluorescence values were background-corrected by subtracting the
signals at the first time point.
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4.3 Results
4.3.1 Hemophilia A model
A commercially available murine FVIII-neutralizing antibody (anti-FVIII) was added to healthy blood
to recapitulate hemophilia A phenotype in our device. We have previously shown that whole blood
perfused over collagen/TF (Fig. 4-1A) could be used to study TF-dependent therapeutics [76]. FVIII
inhibition did not result in marked decreases in platelet accumulation (Fig. 4-1C) but all three doses
of anti-FVIII significantly reduced fibrin generation. In the presence of TF, the effect of FVIII
inhibition only started to manifest at later time points. We have previously used collagen or
collagen/kaolin to activate the contact pathway [82]; however factors such as device surface
treatment and incubation time could influence the onset and the extent of contact activation. Here
we present a modified assay using collagen/FXIa as the surface trigger (Fig. 4-1B) to activate the
intrinsic pathway. On collagen/FXIa surfaces, FVIII inhibition resulted in a slight reduction in platelet
deposition (Fig. 4-1E) after 7 minutes. More importantly, anti-FVIII at concentrations ≥ 25 µg/ml
abolished fibrin generation (Fig. 4-1F). Platelet deposition in FVIII-inhibited blood (Fig. 4-1E) began
to deviate from the control shortly after onset of fibrin polymerization (Fig. 4-1F). We also treated
healthy blood with a neutralizing FVIII-binding antibody (15 µg/ml) derived from hemophilia A
patients (Fig. 4-1 G, H) and similar results were observed.
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Figure 4-1. Hemophilia A assay. Whole blood was perfused over collagen/TF surfaces (A) and
collagen/FXIa surfaces (B) to form thrombi. Murine anti-FVIII (4A4) caused no change in platelet
deposition (C) and a reduction in fibrin generation (D) on collagen/TF. The same concentrations
of the FVIII inhibitory antibody slightly reduced platelet deposition (E) and abolished fibrin
accumulation (F) on collagen/FXIa, similar to results obtained with a patient-derived anti-FVIII (G,
H).
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4.3.2 The effect of an FVIIIa-mimetic bispecific antibody in hemophilia A assay
A humanized bispecific antibody (emicizumab) mimics FVIIIa function and restores hemostasis by
bringing FIXa and FX together to support FX activation. Adding the bispecific antibody to healthy
blood (no anti-FVIII) did not increase platelet accumulation (Fig. 4-2A) but it slightly shortened the
lag time preceding fibrin polymerization (Fig. 4-2B) in a dose-dependent manner. The rate of fibrin
polymerization following the onset appeared to be unchanged since the fibrin generation curves
obtained at different doses can be superimposed by horizontal shifts along the time axis. Similar to
the platelet response in healthy blood, emicizumab did not alter platelet accumulation (Fig. 4-2C)
in our hemophilia A model. In contrast, emicizumab dose-dependently reduced fibrin generation
lag time and increased fibrin polymerization rate (Fig. 4-2D).
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Figure 4-2. Testing emicizumab in hemophilia A assay. The effect of the bispecific antibody on
platelet and fibrin deposition were investigated in healthy blood (A, B) and hemophilia A mimetic
blood (C, D).

The results at the time of control clot occlusion were shown in Figure 4-3 and plotted in bar graphs
(Fig. 4- 3). Neither emicizumab nor the anti-FVIII antibody caused any significant changes in
platelet fluorescence (Fig. 4-3A). All three doses of anti-FVIII (0.01, 0.1, 1 µM) significantly
increased fibrin polymerization (p<0.05, Fig. 4-3B) in whole blood treated with anti-FVIII, with a
modest dose-dependent effect on untreated whole blood. The highest dose (1 µM) of the bispecific
antibody restored fibrin polymerization back to the healthy adult control level (P < 0.05). We also
tested emicizumab in blood obtained from a mild hemophilia patient. Similar to the results in our
hemophilia A assay, platelet accumulation (Fig. 4-4A) was insensitive to emicizumab whereas the
drug dose-dependently rescued fibrin polymerization (Fig. 4-4B) in the hemophilia A patient blood
(7 % of normal FVIII).
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Figure 4-3. The bispecific antibody restored fibrin generation in hemophilia A assay. At the
occlusion time (11min), the bispecific antibody (emicizumab) had no effect on platelet deposition
(A) but it increased fibrin polymerization (B) in both healthy and hemophilia A blood. Representative
images are shown in (C). * P < 0.05.
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Figure 4-4. Emicizumab restored fibrin generation in mild hemophilia A patient blood. The
bispecific antibody had no effect on platelet deposition (A) but it dose-dependently rescued fibrin
polymerization (B). * P < 0.05; ** P < 0.005.
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4.3.3 Hemophilia B model
We used a recombinant FIX variant (reFIX-V181T) to create hemophilia B phenotype. It has been
shown that certain mutations at position 181 (legacy numbering) lead to moderate to severe
hemophilia B [85,86]. FIX-V181T has significantly reduced activity causing prolonged clotting time
in aPTT (activated partial thromboplastin time) assays [87]. When added to healthy blood, lowactivity variants like reFIX-V181T can compete with endogenous FIX to impair FXa generation.
CTI-treated whole blood (± 50 µg/mL FIX-V181T) was perfused over collagen/TF surfaces at an
initial venous shear rate of 100 s-1. Recombinant FIX-V181T reduced both platelet deposition
(Fig.4-5A) and fibrin generation (Fig.4-5B). The FIX variant also reduced platelet accumulation
(Fig.4-5C) and fibrin polymerization (Fig.4-5D) on collagen surfaces with diluted TF (20-fold TF
dilution factor). Although less fibrin was made at low TF in comparison to the high TF condition, the
95% percent inhibition by reFIX-V181T was more pronounced on low TF surfaces providing a larger
dynamic range for the assay.
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Figure 4-5. Hemophilia B assay. Whole blood was perfused over collagen/TF surfaces to form
clots. Recombinant FIX variant inhibited platelet deposition (A) and fibrin generation (B). The same
concentration of reFIX-V181T abolished platelet (C) and fibrin accumulation (D) when TF was
diluted by 20-fold.
4.3.4 The effect of bypassing agents, anti-TFPI or rFVIIa in hemophilia B assay
The use of reFIX-V181T to recreate hemophilia B phenotype allowed us to test the effect of
bypassing agents including anti-TFPI and rFVIIa. Adding anti-TFPI did not significantly affect
platelet accumulation (Fig.4-6A) in healthy adult blood (no reFIX-V181T present) on low TF
surfaces likely because collagen alone was a potent platelet agonist. However all three doses of
anti-TFPI significantly enhanced fibrin polymerization (Fig.4-6B) to the same level. Also, the
control channels occluded by 8 min. When healthy blood was dosed with 50 µg/ml of reFIX-V181T,
anti-TFPI (12 µg/ml) dose-dependently restored platelet deposition (Fig.4-6C) and increased fibrin
polymerization (Fig.4-6D). Concentrations above 12 µg/ml did not cause any significant
enhancement. Adding rVIIa to healthy blood dose-dependently increased platelet deposition
(Fig.4-7A) and fibrin polymerization (Fig.4-7B) on low TF surfaces. However, when blood was
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treated with 50 µg/ml of reFIX-V181T, rFVIIa did not cause any enhancement in platelet and fibrin
accumulation except at 100 nM dose (Fig.4-7C, D).
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Figure 4-6. Testing anti-TFPI in hemophilia B assay. The effect of anti-TFPI on platelet and fibrin
deposition were investigated in healthy blood (A, B) and hemophilia B mimetic blood (C, D).
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Figure 4-7. Testing recombinant FVIIa in hemophilia B assay. The effect of rFVIIa (NovoSeven) on
platelet and fibrin deposition were investigated in healthy blood (A, B) and hemophilia B mimetic
blood (C, D).

4.4 Discussion
Here we report ex vivo hemophilia models that allow the assessment of novel FVIII/FIX
replacements and bypassing agents. The use of a FIX missense variant allowed us to recreate a
HB phenotype. The surface trigger concentration is tunable and can be adjusted to represent
different levels of tissue factor expression in different sites in the body. By reducing the surface
tissue factor concentration, we were able to increase the dynamic range for platelet and fibrin
deposition. Adding anti-TFPI to blood in the presence of reFIX-V181T dose-dependently rescued
platelet deposition and fibrin formation. In contrast, adding anti-TFPI to healthy adult blood did not
alter the platelet response but it did enhance fibrin polymerization at all three doses. This indicates
that anti-TFPI is potentially effective at restoring hemostatic activity in severe hemophilia patients.

66

Adding 20 to 100 nM reFVIIa to healthy blood increased both platelet and fibrin deposition, as
expected given the use of a TF-coated surface. Interestingly, rFVIIa did not significantly alter
platelet deposition in reFIX-V181T-treated blood but it did enhance fibrin polymerization at the
highest dose. The observed weak response to rFVIIa in the presence of reFIX-V181T may possibly
be attributed to the interaction between the exogenously added rFVIIa and reFIX-V181T.
Recombinant FVIIa has been reported to activate FIX on activated platelets [88]. Since the FIX
variant competes with the native FIX in our hemophilia B mimetic assays, it could potentially act as
a sink for rFVIIa.
In the past, we have used blood inhibited with low levels of CTI to investigate hemophilic A
phenotypes on collagen/±TF surfaces. Consistent with the previous observation that high levels of
TF can partially compensate for the FVIII deficiency [76], adding the anti-FVIII inhibitory antibody
to the whole blood from healthy individuals reduced but did not abolish platelet and fibrin deposition.
Platelet accumulation was unaffected possibly due to the strong activation by the collagen trigger
and ADP/thromboxane A2 release. While the TF-dependent pathway alone was able to generate
enough thrombin for fibrin polymerization, all three doses of anti-FVIII reduced fibrin generation
after 5 minutes due to the defect in the FXI-thrombin feedback loop [89]. This reduction in the late
stage fibrin generation was similar to the previously reported results for FXI-inhibited clot formation
[90].

Traditionally, kaolin is used to study TF-independent clotting in healthy/hemophilic blood assays.
Here we developed a new method using collagen/FXIa surfaces to potently and locally activate the
intrinsic pathway. The use of FXIa bypasses the need for FXII activation, therefore blood can be
collected in high levels of CTI (40 µg/mL), which alleviates the need to start the assay right after
the blood collection. In Figure 4, all three concentrations of the murine anti-FVIII (4A4) abolished
fibrin generation on collagen/FXIa within the experimental time frame. This was also true for the
recombinant IgG4 NM41 derived from an inhibitor patient [84]. Because collagen alone was potent
enough to drive platelet aggregation to full occlusion, it was difficult to capture the effect of antiFVIII on platelets. In contrast, the sensitivity and the large dynamic range of fibrin polymerization
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makes the system a good platform to study novel therapeutics such as FVIII-mimetic bispecific
antibodies in a low TF environment. Using this collagen/FXIa based assay, we demonstrated that
emicizumab was able to restore coagulation in hemophilia A blood.
Our microfluidic hemophilia A model was then quantitatively validated by the restoration of fibrin
polymerization in HA-mimetic blood by emicizumab. This ability to allow direct comparison to the
healthy blood clotting profile is an added advantage of our hemophilia assay. Because the time of
blood collection from patients can be unpredictable, it is rather difficult to coordinate a side-by-side
comparison like this between healthy and hemophilic patient blood without having an on-demand
healthy donor available. Using healthy blood not only generates standard curves of normal clot
growth but also provides insights into potential thrombotic risks. For example, emicizumab caused
a small dose-dependent shift towards earlier time points for fibrin generation in blood with normal
FVIII activities. This is likely due to the strong activation of FIX by the concentrated FXIa on the
surface.
4.5 Conclusion
In conclusion, we have developed two hemophilia assays that mimic hemophilia A and B
phenotypes through dosing readily accessible healthy blood with a recombinant FIX variant and an
anti-FVIII inhibitory antibody, respectively. The surface trigger concentration is adjustable and
either collagen/TF or collagen/FXIa can be used depending on the pathway of interest. A limitation
of the models are that they cannot be used to test traditional factor replacement therapeutics
because the FVIII-neutralizing antibody and the recombinant FIX variant will interfere with the
activity of the exogenous factors. Nonetheless, the hemophilia assays could enable rapid
screening/evaluation of novel hemophilic agents in whole blood under flow in a high-throughput
fashion, which helps narrow the therapeutic candidates before testing them in hemophilic patient
blood. The hemophilia assays also have the added advantage of allowing side-by-side
comparisons to clotting at healthy factor levels. Future work is needed to recapitulate different
hemophilia severities/residual factor levels using different anti-FVIII/reFIX doses. Surface platelet
trigger can be optimized to increase the dynamic range for platelet deposition by reducing thrombinindependent platelet activation/aggregation. In addition, patient-derived neutralizing antibodies and
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factor variants can be explored to predict the effect of therapeutics in hemophilia subjects with the
specific inhibitors/mutations.
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Chapter 5: Neonatal hemostasis and thrombosis
5.1 Introduction
Arterial thromboembolic disease is becoming the new epidemic of pediatric tertiary care centers
due to an increase in invasive monitoring, life-saving technologies such as extracorporeal
membrane oxygenation (ECMO), and new surgical techniques and graft materials used to repair
complex congenital heart disease (CHD). However, therapeutic options for preventing or treating
this life and limb threatening disorder are limited. Major obstacles to drug development include: (i)
A deficiency in knowledge of the extent to which platelets from neonates can form thrombi in injured
blood vessels, (ii) limited information on the ability of various agents to curtail pediatric platelet
adhesion and activation under physiologically relevant conditions, and (iii) a lack of sophisticated
technologies that permit rapid evaluation of pediatric platelet responses to agonists and antagonists
in a high-throughput manner using a minimum quantity of blood. Microfluidic devices uses low
volume of blood and provide a physiologically relevant platform for the prediction of pediatric
platelet responses to various drugs and their possible combinations. The microfluidic clotting
assays can also be used for the assessment of in vivo drug efficacy in the prevention of thrombosis.
Under normal conditions, neonatal platelets have been described as hyporeactive compared to
adult platelets [91]. The conventional methods of assessing platelet activity (often using cord blood)
include: (i) measurement of Annexin V binding to phosphatidylserine (PS) detected by flow
cytometry, (ii) staining of P-selectin, a marker of alpha granule release, (iii) binding of PAC-1, an
antibody that only recognizes the active form of IIb3, which enables fibrinogen-mediated plateletplatelet adhesion (platelet aggregation), and (iv) measurement of thromboxane generation.
Coagulation also plays an important role in maintaining hemostasis. Routine lab assays such as
prothrombin time and partial thromboplastin time all show prolonged clotting time and reduced
thrombin potential in neonates compared with adults. This is a result of their lower levels of
coagulation factors. However healthy neonates clinically present excellent hemostasis. This is likely
because neonatal patients also have lower levels of naturally occurring anticoagulants [92]. One
study has found that thrombin potential in neonates was comparable to adults when small amounts

70

of tissue factor was used [93], in contrast to the reduced levels compared to adults upon strong
activation. However, the tissue factor level in cord blood has been found to be significantly higher
than that in adults [94]. Whether this is true in peripheral neonatal blood is not clear.
While all those studies provide invaluable insights into the differences in individual components of
the hemostatic system between adults and neonates, platelet aggregation and coagulation are
tightly linked together. Platelet membranes act as catalytic surfaces for thrombin generation, which
could in turn activate platelets through protease-activated receptors (PAR). Some studies have
reported lower levels of PAR1 and PAR4 in neonates [95]. Using our flow assay, we were able to
study platelet deposition and thrombin/fibrin generation simultaneously on collagen/TF surfaces
before and after surgical operations. In addition to characterizing the hemostatic activity in neonatal
peripheral

blood,

we

also

utilized

the

microfluidic

platform

to

investigate

neonatal

platelet/coagulation responses to thrombin receptor inhibition and direct FXa inhibition.
For neonatal patients with systemic-to-pulmonary shunts, low-dose aspirin 12 hours after the
surgical operation has been the go-to therapy for the prevention of long-term complications [96]. In
a large multicenter observational trial, receiving low-dose aspirin reduced risk of shunt thrombosis
(P=0.008) and death in infants palliated with aortopulmonary shunts [97]. The downside of aspirin
is that it is irreversible and a study has shown that aspirin alone may not be adequate for shunt
prophylaxis in the immediate post-operative period [98]. Clopidogrel is a potent oral antiplatelet
agent that irreversibly block adenosine diphosphate receptor (P2Y 12) on platelet membranes, and
it has been investigated as a potential prophylactic agent. A clinical trial evaluating clopidogrel
therapy in infants with a systemic-to-pulmonary artery shunt did not show any benefit in reducing
death rate or shunt-related morbidity in patients that already received conventional anticoagulation
[99]. However, the dosage of the drug administered was low and the majority of patients (88%)
received the concomitant administration of aspirin, making it difficult to evaluate the efficacy of
targeting P2Y12. Cangrelor is another P2Y12 receptor antagonist and it is used through intravenous
(IV) administration, which is more advantageous compared to the oral administration of clopidogrel
as the latter could results in erratic adsorption and delay in the onset of action due to the need for
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conversion into an active metabolite. The reversibility of cangrelor and its rapid inactivation in the
circulation by dephosphorization to the nucleoside independent of liver/renal function also means
it can be used in a more controlled and predicable fashion. In healthy adult volunteers, restoration
of hemostasis began within 10 min of cessation of cangrelor infusion and full platelet function
recovered within 60 min. The drug has been proved by FDA in 2015 for use in adults undergoing
percutaneous coronary intervention. Here we used our microfluidic device to evaluate the efficacy
of cangrelor intravenous administration in reducing post-operative shunt thrombotic risks in
neonatal patients.
5.2 Materials and Methods
5.2.1

Patient enrollment

For the investigation of neonatal hemostasis and responses to FXa/PAR1 inhibition, neonates (<28
days of life) with known CHD were enrolled. Exclusion criteria included coagulation defects, known
congenital or genetic conditions expected to affect platelet function, body weight <3 kg,
cardiopulmonary instability necessitating urgent or emergent surgical/catheter-based intervention,
requirement of shunt placement, and medications or other conditions that affect platelet function.
For the assessment of clotting profile before, during, and after receiving post-operational cangrelor
IV administration, neonatal patients that met the following inclusion criteria were eligible for
enrollment: (i) cardiac participants with placement of systemic-to-pulmonary artery palliative
shunts, right ventricle to pulmonary artery palliative shunts, or ductus arteriosus stents who are at
risk of thrombotic events after repair for structural congenital heart disease, and (ii) life expectancy
of at least 15 days at study entry. Exclusion criteria are listed below:
1. History of intracerebral bleed (confirmed by a ultrasound (US) of the head prior to surgery),
or cerebral arteriovenous malformation, or any prior bleed with neurological deficit
2. Gastrointestinal or urinary bleeding
3. Cerebrovascular accident or any cerebrovascular accident with a residual neurological
deficit
4. Known congenital or acquired bleeding or clotting disorder
5. Weight less than 2.5 kilograms (kg)
6. Adjusted gestational age less than 37 weeks
7. Platelet count less than 100,000 cells/microliter (µL)
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8. Chest and/or mediastinal tube blood output of greater than 3 milliliters (mL)/kg/hour (hr) at
the time of cangrelor administration
9. Participants with evidence of severe hepatic or renal failure [aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) greater than three times normal for age or total
bilirubin greater than 20 milligrams (mg)/deciliter (dL); creatinine greater than 2 times the
normal upper limit]
10. Known allergy to cangrelor or known sensitivity to any component of cangrelor
11. Any condition that in the investigator's opinion would constitute a contraindication to
participation in the study or cause inability to comply with the study requirements
12. Participation in another investigational therapeutic drug or investigational therapeutic
device trial within 30 days of starting study
13. Participants who have been receiving warfarin (Coumadin®) therapy
5.2.2

Materials

Reagents were obtained as follows: Alexa Fluor 488 conjugated anti-human CD61 (Bio-Rad,
Raleigh, NC, USA), Alexa Fluor 647 conjugated human fibrinogen (ThermoFisher Scientific, Grand
Island, NY, USA), type I fibrillar collagen (Chrono-log, PA, USA), Dade Innovin lipidated tissue
factor (Siemens, Malvern, PA, USA), corn trypsin inhibitor (Haematologic Technologies, Essex
Junction, VT, USA), apixaban (SelleckChem, Houston, TX), HEPES (Fisher Scientific, Hampton,
NH), Bovine serum albumin and Sigmacote (Sigma, St. Louis, MO, USA).
5.2.3

Surface patterning

For surface coating, a single 250-µm wide channel polydimethylsiloxane (PDMS) patterning device
was vacuum-sealed to a Sigmacote-treated glass slide, as previously described. Collagen (5 µl,
0.75 mg/ml) followed by lipidated tissue factor (TF, 7 nM, 5 µl) was perfused through the channel
and incubated under static conditions for 30 min. The channel was then rinsed with 20 µl of 1%
bovine serum albumin (BSA) in HEPES-buffered saline (HBS). The patterning device was
subsequently replaced by an 8-channel PDMS device positioned perpendicular to the surface
pattern stripe to form 8 uniformly distributed prothrombotic patches (250 µm x 250 µm).
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5.2.4

Blood collection and preparation

Patient blood samples were obtained from a central venous catheter after clearing the line of
heparin; blood samples from healthy adult subjects were obtained via routine venipuncture.
Informed consent was obtained before all blood draws from healthy adults and parents of neonates
by using a protocol approved by the institutional review committees at Columbia University Medical
Center and University of Pittsburgh.
For ex vivo evaluation of neonatal platelet response to anticoagulants/antiplatelets, blood (1 ml)
was collected via venipuncture into a syringe containing the FXIIa inhibitor CTI (40 µg/ml) to prevent
contact pathway activation. Platelets were labeled with anti-human CD61 (0.05mg/mL stock, 1:50
v/v% in blood). Fluorescently conjugated fibrinogen was added (1mg/mL stock, 1:80 v/v% in blood)
to track thrombin generation and fibrin polymerization.
For the microfluidic assessment of IV administration of cangrelor in neonatal patients getting
systemic-to-pulmonary artery shunts, blood (1 ml) was collected into a tube containing Factor IIa
inhibitor PPACK (100 µM). For each patient, the first blood draw took place 8 hours after surgery.
IV administration of cangrelor began 9 hours after surgery and lasted an hour. The second blood
draw took place 45 minutes into the infusion. Participants received 0.5 µg/kg/min in cohort 1, and
half the dose in cohort 2. The third blood draw took place 11 hours after surgery or 1 hour after
infusion. Platelets were labeled with anti-human CD61 (0.05mg/mL stock, 1:50 v/v% in blood).
A constant outlet flowrate was set by a syringe pump to achieve a well-defined initial venous shear
rate of 200s-1 (Fig. 5-1A).
5.2.5

Imaging

Platelet and fibrin were detected by an epifluorescence microscopy (Leica DMi8). A 10X
objective/0.32 NA was used in all of the experiments. Clot formation was imaged for 15 minutes
with a 60-sec time interval. ImageJ (NIH) was used to analyze acquired images. The mean
fluorescent intensity was measured over the central 75% of the channel to eliminate side-wall
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effects. The fluorescence values were background-corrected by subtracting the images at the first
time point.
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5.3 Results
5.3.1

Reduced platelet response and thrombin generation in neonates

Blood from 11 adults all formed occlusive thrombi on collagen/TF in microfluidic devices. In
contrast, 15 min-perfusion of neonatal blood failed to form occlusive clots for 9 out of 14 patients
(Fig. 5-1B). At the average adult clot occlusion time (8 min), adult platelet deposition was 3-fold
greater than the neonatal platelet deposition (Fig. 5-1B). Data after population-averaged occlusion
time were omitted as clot embolization could complicate data interpretation. In addition to reduced
platelet deposition, neonate patients also had slower thrombin generation compared to adults,
reflected by their lower fibrin response. Overall neonate patients appeared to have impaired clotting
rates.
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Figure 5-1. Evaluation of neonatal hemostatic activity in microfluidic assays. CTI-treated
blood was perfused over collagen/TF at a venous shear rate (A). The percentage of donors with
occlusive thrombi was plotted as a function of time (B). Neonates have lower platelet deposition
(C) and fibrin polymerization.

5.3.2

Heightened sensitivity to FXa inhibitor in neonates

We then evaluated neonatal response to FXa inhibition and PAR1 antagonism. When making
comparisons between neonates and adults, we used the data at the occlusion time point or the last
time point (15min) for each donor to reduce the impact of slower platelet/fibrin deposition in
neonatal blood. The average platelet and fibrin fluorescent intensities were depicted in Figure 52A and Figure 5-2B, respectively. At each donor's occlusion time, average adult platelet deposition
was still higher than the average neonatal platelet deposition, while the average fibrin FIs were
similar between the two control groups.
Adding 0.25 µM apixaban to adult blood resulted in a 50% decrease in fibrin deposition (Fig. 5-2D)
without affecting platelet accumulation (Fig. 5-2C). Higher doses (0.5 µM and 1 µM) caused
statistically significant reductions to both platelet and fibrin FIs. For neonatal patients, 0.25 µM, 0.5
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µM, and 1 µM apixaban reduced platelet and fibrin deposition (Fig. 5-2 E-F) in a dose dependent
manner. All three concentrations showed greater inhibition in neonatal platelet deposition (Fig. 52G) compared to adult platelet response. While neonatal fibrin polymerization (Fig. 5-2H) were also
more sensitive to the low dose apixaban (0.25 µM) compared to adults, this difference was less
significant at the medium concentration (0.5 µM) and disappeared at the highest concentration (1
µM).
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Figure 5-2. Adult and neonatal responses to apixaban. Data at the occlusion time (or 15 min if
clots were nonocclusive) were averaged for all subjects. The raw fluorescent intensities (FIs) were
shown for both platelet (A) and fibrin deposition (B). FIs were normalized for each adult (CD) and
averaged for each condition group. Similarly, normalized results for neonatal patients were shown
in (EF). The extent of inhibition in platelet (G) and fibrin (H) accumulation were compared between
adults and neonates. Adult: N ≥ 11 donors, n ≥ 46 clots; Neonatal patient: N ≥ 13 donors, n ≥ 63
clots. *: P<0.005, **: P<0.05, n.s.: not significant. Unless otherwise stated, P<0.005(*) between any
two groups in (CF).
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5.3.3

Heightened sensitivity to PAR1 inhibitor in neonates

Next we tested the efficacies of PAR1 inhibition. While vorapaxar obtained FDA approval for
reducing myocardial infarction and stroke risks in adults, atopaxar more potently inhibited ex vivo
clot formation at 100 µM (Fig. 5-3 A, B), consistent with other reports on PAR1 inhibition albeit in
different cell types. For this reason, atopaxar was used in this study to evaluate differences in
platelet/fibrin response to PAR1 inhibition between adults and neonates. Because of the high
dosages used in this study, DMSO was added to help prevent solubility issues. A concentration of
0.5 v/v% of DMSO was maintained across all groups for both populations. Figure 5-4 shows that
inhibiting PAR1 receptors did result in differential inhibitory effects on neonate and adult clot
formations in our microfluidic devices. Similar to the analysis applied to the apixaban experiments,
data at each donor’s occlusion time point were used and FIs from all conditions were normalized
to the averages FIs of the control groups to reduce the impact of clotting rate differences between
the two populations (Fig. 5-4C). All three concentrations of atopaxar (50, 100, 150 µM) dosedependently reduced platelet deposition (Fig. 5-4A), and the inhibitory effects was stronger in adult
blood than in neonatal blood. Increasing atopaxar dosage only offered minimal benefit to the
reduction of fibrin polymerization (Fig. 5-4B) for both populations.

80

Figure 5-3. Adult response to atopaxar and vorapaxar. 100 µM atopaxar resulted in a larger
reduction in platelet deposition (A) compared to vorapaxar at the same concentration. Fibrin
responses (B) were similar.
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Figure 5-4. Adult and neonatal responses to Atopaxar. Data at the occlusion time were
averaged for all subjects. FIs were normalized for each subject and averaged for each condition
group. Platelet FIs were shown in (A), fibrin FIs were shown in (B), and occlusion times were plotted
in (C). Adult: N ≥ 8 donors, n ≥ 29 clots; Neonatal patient: N ≥ 5 donors, n ≥ 22 clots. *:P<0.005;
**:P<0.05; n.s.: not significant.

5.3.4

Increased platelet activity after surgeries

We also measured neonatal response before and after surgeries for 13 patients. The pre-op and
post-op platelet/fibrin depositions at 300 sec were shown side-by-side for comparison. For Patient
(Pt) 02-012, the data at 240 sec were used instead because post-op clots embolized before 300
sec. For the majority of the patients except Pt 47 and Pt 02-008, platelet deposition increased after
surgeries (Fig. 5-5A). This was also reflected in their shortened clot occlusion time (Fig. 5-5C). In
contrast, 7 out of 13 of those patients had similar level of fibrin generation (Fig. 5-5B) before and
after surgeries.
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Figure 5-5. Adult and neonatal hemostatic activity before and after surgical operations. FIs
were normalized for each subject. Platelet FIs were shown in (A), fibrin FIs were shown in (B), and
occlusion times were plotted in (C). *:P<0.005; **:P<0.05; n.s.: not significant.
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5.3.5

Efficacy and safety of cangrelor IV administration in neonates after shunt
placements

Microfluidic clotting assays were also used for the assessment of the efficacy and the safety of
post-op cangrelor treatment in neonates with placement of systemic-to-pulmonary artery palliative
shunts, right ventricle to pulmonary artery palliative shunts, or ductus arteriosus stents who are at
risk of thrombotic events after repair for structural congenital heart disease. Representative images
of platelet deposition were shown in Figure 5-6. The patient platelets (Fig. 5-6A) 8 hours after
surgical operation accumulated faster than adult platelets on collagen in the same devices. After
45 minutes IV administration of 0.5 µg/kg/min cangrelor, blood was collected again from the patient,
whose platelet deposition (Fig. 5-6B) dropped below both the adult level. While platelets in neonatal
blood were still able to adhere to collagen to maintain hemostasis, the secondary aggregation of
platelets was for the most part abolished. The final blood draw for the microfluidic assessment took
place 1 hour after another 15 min of cangrelor infusion. The reversibility of the antiplatelet drug is
demonstrated in Figure 5-6C.
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Figure 5-6. Ex vivo evaluation of neonatal patient platelet activity (Patient 5) in microfluidic
clotting assays. Patient platelet deposition was compared side-by-side with adult platelet
deposition on collagen before (A), during (B), and after (C) IV administration of cangrelor.

We compared patient platelet responses before, during, and after cangrelor infusions. While 45 min
of cangrelor infusion strongly reduced platelet deposition, this inhibitory effect diminished just 1
hour after the drug administration (Fig. 5-7).
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Figure 5-7. Representative patient platelet deposition (Patient 5) on collagen before, during,
and after the cangrelor infusion.

In cohort 1, a concentration of 0.5 µg/kg/min was used for cangrelor infusion for safety evaluation.
In cohort 2, the dosage was halved to 0.25 µg/kg/min. Platelet inhibition at 300s for 4 patients in
cohort 1 and 5 patients in cohort 2 were summarized in Figure 5-8A. On average, 45 min of 0.5
µg/kg/min cangrelor administration resulted in a 67% inhibition in platelet accumulation, and platelet
disposition was only restored to 75% of the pre-infusion level 1 hour after the 60 min IV infusion. In
contrast, 45 min of 0.25 µg/kg/min cangrelor administration led to a 59% inhibition in platelet
accumulation, and platelet deposition fully restored to the pre-infusion level 1 hour after the IV
infusion. Platelet FIs at 300 sec were also shown for individual patients. In cohort 1 (Fig. 5-8B), the
high dose of cangrelor (0.5 µg/kg/min) resulted in strongest inhibition (75%) for patient 2, and the
platelet activity only recovered to 43% of its original level. The same dose of cangrelor caused a
72% reduction, a 50% reduction, and a 67% reduction for patient 3, patient 4, and patient 5,
respectively. While patient 3 and 4 had slightly lower platelet deposition compared to the levels
before the infusion, the differences were statistically insignificant. In cohort 2 (Fig. 5-8C), the
reduced dose of cangrelor (0.5 µg/kg/min) decreased platelet accumulation on collagen by 54%,
65%, and 63% for Pt 6, Pt 0013, and Pt 02-0001, respectively. All three patients had platelet activity
fully restored to the pre-infusion level. The 45 min of cangrelor infusion resulted in a 57% inhibition
in platelet deposition for Pt 02-0002. An hour after the 60 min cangrelor administration, platelet
deposition for this patient was restored to 93% of the pre-infusion level, and this difference was
statistically significant (P<0.01). Interestingly, while the same treatment reduced platelet deposition
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on collagen by a similar amount (53%) for Pt 0014, the patient actually had higher platelet activity
an hour after the cangrelor administration.

Figure 5-8. Percentage platelet deposition on collagen before, during, and after cangrelor
infusions for all patients. The results from 4 cohort 1 patients and 5 cohort 2 patients were
averaged (A). Cohort 1 results for individual patients were shown in (B). Cohort 2 results for
individual patients were shown in (C). *: P<0.001, **: P<0.01, n.s.: not significant.
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5.4 Discussion
We observed slower platelet deposition in neonatal blood than in adult blood on collagen/TF
surfaces under flow. At the concentration of TF used in our assay, neonates also had slower TFinduced thrombin generation and fibrin polymerization. Interestingly, despite the large difference in
platelet deposition between the two populations (67% lower platelet FI for neonates at 8 min), which
could affect the abundance of the catalytic surfaces available for thrombin generation, fibrin FI was
only 39% lower for neonates at 8 min. Our observation of hypo-functional platelets and reduced
thrombin generation in neonatal whole blood clot formation was in agreement with previous studies
using isolated platelets and plasma.
While we could look at neonatal and adult responses to apixaban and atopaxar at a fixed time point,
the large difference in their platelet deposition, fibrin accumulation, and occlusion time makes it
difficult to find a perfect reference point. Although the inhibitory effects of the drugs can also vary
with time, we chose the data at each donor’s occlusion time point (or 15 min if clots remain
nonocclusive) to maximize the dynamic range and then normalized the values for each donor. The
average responses showed that 0.25 µM apixaban was effective at reducing adult fibrin generation
by 49% and neonatal fibrin polymerization by 67%. For reasons not entirely clear, neonatal
thrombin/fibrin generation is more sensitive to direct FXa inhibition at low doses compared to adults.
This difference in percentage fibrin inhibition diminished with increasing concentration of apixaban.
Interestingly, 0.25 µM apixaban did not affect adult platelet accumulation but it did decrease the
neonatal platelet deposition to 62% of the control level, which may be attributed to blunted
thrombin-induced platelet activation and impaired thrombin-induced platelet aggregation. Such
differential effects on PAR-mediated platelet activation has been documented before between the
two populations [100].
PAR1 antagonism using 50 µM atopaxar resulted in reduced platelet accumulation in neonates,
which is likely due to the aforementioned defect in PAR1-mediated platelet activation and
aggregation among neonates [100]. Increasing the dosage of atopaxar further reduced platelet
deposition for both populations, and the extent of those reductions were similar between the adult
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donors and the neonatal patients. While atopaxar is an antiplatelet agent, its influence on platelet
activity also affected thrombin generation, reflected by the reduction in fibrin polymerization. This
indirect inhibitory effect on thrombin production may be attributed to reduced availability of platelet
membrane procoagulant surfaces for the assembly of coagulation protease complexes. While
higher doses of atopaxar (>100 µM) inhibited adult and neonatal platelet depositions to the same
degree, the difference in normalized fibrin generation between the two population groups persisted.
Both PAR1 antagonism and direct FXa inhibition could curtail the dire effect of excessive thrombin
generation. Despite causing liver toxicity issues in a previous clinical trial, atopaxar was more
potent than FDA-approved vorapaxar at 100 µM and was only used here for research purposes to
help us gain insights into the effectiveness of those two approaches. Compared to adults, neonates
display heightened sensitivity to both atopaxar and apixaban at lower doses. A downside of our
study is that in our microfluidic devices, we cannot evaluate the effect of PAR1 inhibition on
endothelial cells, which also express PARs. Vorapaxar has been shown to inhibit all signaling
downstream of endothelial PAR1 and cause endothelial injury [101]. A novel class of small
molecule PAR antagonists, paramodulins, are able to inhibit PAR1-mediated prothrombotic and
proinflammatory pathways without blocking active protein C (APC)-mediated pathways or harming
endothelium. Future studies could look into the potency of paramodulins in neonatal blood ex vivo
if PAR1 inhibition is being sought after. Another way to curb thrombin-mediated thrombi formation
is to reduce thrombin generation. Whereas targeting thrombin directly using drugs such as
dabigatran lowers major-bleeding risks and all-cause mortality compared to warfarin treatment, it
has been shown to increase the risk of myocardial infarction, which was not observed for FXa
inhibitors such as apixaban and Rivaroxaban. In addition, while expensive, the effects of those FXa
inhibitors can now be reversed by a recently FDA-approved reversal agent andexanet alfa to
prevent potential bleeding.
In addition to characterizing the hemostatic activity and potential efficacy of FXa/PAR1 inhibition in
neonates, we also measured and compared their pre-op and post-op platelet/fibrin deposition
levels. Many of the patients went on bypass and were given blood products to reduce bleeding
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risks; however, this has resulted in an increase in overall platelet activity and a decrease in overall
occlusion time beyond the pre-op level. While the change was only modest for some patients whose
post-op platelet accumulation rate did not exceed the average level for adults, those patients may
still have increased thrombotic risks as the low level platelet activity observed in the pre-op assay
results may already be enough for maintaining good hemostasis in healthy neonates. Out of the 13
patients, 5 of them also had an increase in fibrin production after surgical operations, and 1 patient
had a small reduction in fibrin generation. Additional patient information and treatment details need
to be collected to draw further conclusions from those results.
While the thrombin story is less clear, most of the neonatal patients with CHD displayed
upregulated platelet activity likely due to hemodilutions in cardiopulmonary bypass and
intraoperative blood products. Among neonatal patients with CHD, those with single-ventricle
physiology who require placement of a systemic-to-pulmonary artery shunt are at greatest risk of
developing thrombosis in the immediate post-operative period. Indeed, side-by-side comparison
demonstrated that post-op neonatal platelet deposition could surpass adult levels even in the
absence of thrombin generation. Intravenous administration of cangrelor for 45 min successfully
reduced platelet deposition below the adult level for all patients enrolled in the clinical trial.
Additionally, restoration in platelet activity on collagen was evident 1 hour after the infusions. On
average, reducing the therapeutic dosage by half from 0.5 µg/kg/min in cohort 1 to 0.25 µg/kg/min
in cohort 2 resulted in a decrease in percentage platelet inhibition both during infusion (8%) and
after infusion (25%).
5.5 Conclusion
In conclusion, we have characterized clotting profiles and found reduced platelet aggregation and
fibrin polymerization in neonatal patients with CHD compared to healthy adults. Those neonates
also had heightened sensitivity to FXa inhibition and PAR1 antagonism. After surgical operations,
their platelets transitioned from “hypofunctional” to “hyperreactive”. Post-operational IV
administration of the antiplatelet agent, cangrelor, rapidly and reversibly reduced thrombotic risks
amongst patients that received shunt placements.
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Chapter 6: Future work
6.1 Effect of blocking mechanosensitive cation channels
While platelet function and thrombus growth are influenced by hemodynamic forces, we are only
beginning to understand the role of mechanosensitive (MS) channels in platelets [102].
Pharmacological reagents such as the MS channel Piezo 1 inhibitor Grammostola spatulata
mechanotoxin 4 (GsMTx-4) and the agonist Yoda1 are useful tools for elucidating the contribution
of MS channels in shear-induced platelet activation/aggregation. Interestingly, Piezo1 is also
involved in erythrocyte volume homeostasis and T cell activation [103,104]. When Yoda1 was
added to PPACK blood perfused over collagen under venous condition in one experiment, we only
observed similar near-zero levels of extracellular DNA signal. However, we cannot exclude the
possibility of Piezo1 playing a role in shear-induced NETosis. Future work is needed to investigate
whether Yoda1 could enhance NET release under arterial pressure drops and more importantly
whether inhibiting Piezo1 with GsMTx-4 could attenuate shear-induced NETosis. Interestingly,
platelet aggregation appeared to be more stable in the presence of Piezo1. While this effect was
difficult to quantify when we averaged the platelet intensity over the entire clot areas, it was evident
when we only averaged over the front portion (25% of the area) of the clots. More experiments are
needed to verify this phenomenon.
6.2 Drug testing in hemophilia patient blood
While the microfluidic hemophilia assays using dosed adult blood is useful for studying novel
therapeutics such as bypassing agents, patient blood is still needed to evaluate the efficacies of
various FVIIIs. Adding Advate (a commercial FVIII), emicizumab, and a Bioverative FVIII to blood
from a mild hemophilia patient restored fibrin generation to different degrees (Fig. 6-1). A larger
sample size is needed to confirm the potency of the drugs.
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Figure 6-1. Advate, emicizumab, and another FVIII product were added to blood obtained
from a mild hemophilia patient. Blood was then perfused over collagen/FXIa surfaces.

6.3 Characterization of hemophilia patient-derived antibodies
The collagen/FXIa surface based clotting assay can also be used to evaluate the activity of
hemophilia patient-derived antibodies or factor variants. Blood treated with CTI (40 µg/ml) was
incubated with FVIII-binding antibodies for 15 minutes and perfused over collagen/FXIa (Fig. 6-2).
Interestingly even NIBSC1, which was derived from healthy donor and did not show FVIII
neutralizing activities in conventional assays, dose-dependently inhibited fibrin polymerization
under flow albeit only by a smaller percentage compared to other inhibitors. The assay not only
enables the characterization of the patient-derived antibodies, it can also be used to predict
individual patient’s response to novel therapeutics in the future.

92

Normalized Fibrin FI

2.0

1.5

NIBSC1
NIBSC2
NIBSC3
NIBSC4
NIBSC5

1.0

0.5

0.0
0 ug/ml

1.5 ug/ml

5 ug/ml

15 ug/ml

Figure 6-2. Healthy donor (NIBSC1) and patient-derived antibodies (NIBSC2-5) were added
to healthy blood collected in CTI. Blood was then perfused over collagen/FXIa surfaces at
100s-1.

6.4 Optimization of surface platelet trigger in clotting assays
The microfluidic hemophilia A assay demonstrated good dynamic ranges in terms of fibrin
polymerization, but platelet deposition was less sensitive to direct intrinsic pathway inhibition. In
addition, fibrin generation onset on collagen/FXIa is delayed compared to the conventional
collagen/TF-based assays. Therapeutics that depend on the intrinsic pathway can only show effect
after this fibrin polymerization onset and before clots reach full occlusion. Therefore it would be
beneficial to delay the channel occlusion time, which could potentially increase the dynamic range
for both platelet and fibrin measurements. Lower concentrations of the fibrillar collagen could be
used as long as uniform clots can be obtained. Alternatively, other proteins such as von Willebrand
factor, poly-L-lysine or combos could be explored to enable initial platelet adhesion to a localized
surface patch without causing too much platelet activation.
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